[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3263
1. Hsu IC, Bae K, Shinohara K, Pouliot J, Purdy J, Ibbott G, Speight J, Vigneault E, Ivker R, Sandler H: Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys; 2010 Nov 1;78(3):751-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321.
  • PURPOSE: To estimate the rate of late Grade 3 or greater genitourinary (GU) and gastrointestinal (GI) adverse events (AEs) after treatment with external beam radiotherapy and prostate high-dose-rate (HDR) brachytherapy.
  • Patients with locally confined Stage T1c-T3b prostate cancer were eligible for the present study.
  • The pretreatment characteristics of the patients were as follows: Stage T1c-T2c, 91%; Stage T3a-T3b, 9%; prostate-specific antigen level ≤10 ng/mL, 70%; prostate-specific antigen level >10 but ≤20 ng/mL, 30%; and Gleason score 2-6, 10%; Gleason score 7, 72%; and Gleason score 8-10, 18%.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):851-8 [10705005.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):814-9 [18407435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):343-52 [10802358.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):61-9 [11163498.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):1021-31 [11429230.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):81-90 [11777625.001]
  • [Cites] J Urol. 2003 Mar;169(3):974-9; discussion 979-80 [12576825.001]
  • [Cites] Radiother Oncol. 2003 Sep;68(3):285-8 [13129636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1063-71 [15001246.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Dec 1;33(5):1019-27 [7493828.001]
  • [Cites] Radiother Oncol. 1997 Sep;44(3):237-44 [9380822.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):525-33 [9635698.001]
  • [Cites] Radiother Oncol. 1998 Aug;48(2):197-202 [9783892.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1095-101 [10192361.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):747-8 [10386630.001]
  • [Cites] Strahlenther Onkol. 1999 Jun;175 Suppl 2:87-8 [10394408.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):804-9 [16289906.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2006;9(3):245-53 [16786040.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):416-23 [16879929.001]
  • [Cites] Cancer. 2007 Apr 15;109(8):1506-12 [17340591.001]
  • [Cites] Radiother Oncol. 2007 Aug;84(2):114-20 [17531335.001]
  • [Cites] J Appl Clin Med Phys. 2007;8(4):2415 [18449148.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1205-11 [10725633.001]
  • (PMID = 20207506.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA32115; United States / NCI NIH HHS / CA / U24 CA081647; United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / U10CA37422; United States / NCI NIH HHS / CA / U24 CA81647; United States / NCI NIH HHS / CA / U10 CA037422; United States / NCI NIH HHS / CA / U10 CA021661; United States / NCI NIH HHS / CA / U10 CA032115
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS209285; NLM/ PMC2946454
  •  go-up   go-down


2. Kitley CA, Mosier AD, Keylock J, Nguyen D: Malignant priapism secondary to adenocarcinoma of the prostate. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant priapism secondary to adenocarcinoma of the prostate.
  • The authors report a case of an older gentleman with a history of metastatic prostate cancer who presented to the emergency department following 3 weeks of progressively intermittent and then continuous priapism.
  • [MeSH-major] Adenocarcinoma / diagnosis. Penile Neoplasms / secondary. Priapism / etiology. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy, Large-Core Needle. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Diagnosis, Differential. Disease Progression. Fatal Outcome. Follow-Up Studies. Humans. Image Interpretation, Computer-Assisted. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Palliative Care. Penis / pathology. Prostate / pathology. Tomography, X-Ray Computed. Urinary Bladder / pathology

  • Genetic Alliance. consumer health - Priapism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiographics. 2001 Oct;21 Spec No:S283-98; discussion S298-9 [11598264.001]
  • [Cites] J Androl. 2003 Jul-Aug;24(4):499-500 [12826689.001]
  • [Cites] Radiol Clin North Am. 2004 Mar;42(2):427-43 [15136026.001]
  • [Cites] Eur Urol. 1987;13(5):351-2 [3315692.001]
  • [Cites] Urol Int. 1994;52(1):52-4 [8140683.001]
  • [Cites] Urology. 1998 Feb;51(2):324-6 [9495721.001]
  • [Cites] J Surg Oncol. 1998 May;68(1):51-9 [9610664.001]
  • [Cites] Urol Clin North Am. 2007 Nov;34(4):631-42, viii [17983902.001]
  • (PMID = 22789733.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028547
  •  go-up   go-down


3. Hung CF, Lee CH, Hung SW, Chiu KY, Cheng CL, Yang CR, Chen CJ, Li JR: Invasive adenocarcinoma of the prostate with urethral tumor. J Chin Med Assoc; 2010 Feb;73(2):101-3
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive adenocarcinoma of the prostate with urethral tumor.
  • Metastases of prostate cancer to the penis and urethra are rare and often represent advanced disease.
  • We describe a case of newly diagnosed prostatic adenocarcinoma with metastases to the corpus spongiosum, cavernosum, and the anterior urethra.
  • His prostate-specific antigen level was 5.02 ng/mL.
  • Digital rectal examination disclosed stony hard tumors at both lobes of the prostate.
  • Transrectal ultrasound-guided biopsy of the prostate revealed adenocarcinoma over both lobes; the Gleason score was 4 + 4 = 8.
  • Cystoscopy showed a penile urethral tumor and biopsy disclosed metastatic adenocarcinoma of the prostate; the Gleason score was 4 + 4 = 8.
  • The patient died in the 25(th) month after the diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology. Urethral Neoplasms / secondary
  • [MeSH-minor] Aged. Humans. Male. Prognosis. Prostate-Specific Antigen / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20171591.001).
  • [ISSN] 1728-7731
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


Advertisement
4. Kluger N, Guillot B: Sign of Leser-Trélat with an adenocarcinoma of the prostate: a case report. Cases J; 2009;2:8868

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sign of Leser-Trélat with an adenocarcinoma of the prostate: a case report.
  • Even though this sign remains controversial, it has been described during a wide range of malignancies, including mainly adenocarcinoma of the gastro-intestinal tract or the breast.
  • CASE PRESENTATION: We report the case of a 68-year-old man who experienced sudden increased in number of seborrheic keratoses within two years prior to a diagnosis of adenocarcinoma of the prostate.
  • CONCLUSION: This is the second case of adenocarcinoma of the prostate associated with the sign of Leser-Trélat.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1996 Jul;35(1):88-95 [8682971.001]
  • [Cites] Arch Dermatol. 1975 Jun;111(6):792-3 [1169918.001]
  • (PMID = 19918348.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2769478
  •  go-up   go-down


5. Amato RJ, Hernandez-McClain J, Henary H: Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate. Urol Oncol; 2009 Jan-Feb;27(1):8-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate.
  • OBJECTIVE: To assess the efficacy of granulocyte macrophage colony-stimulating factor (GM-CSF) in combination with thalidomide on prostate-specific antigen (PSA) reduction in hormone-naïve prostate carcinoma (HNPC) patients with rising PSA levels after definitive local treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Prostatic Neoplasms / drug therapy. Thalidomide / administration & dosage
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Synergism. Humans. Male. Middle Aged. Prostate-Specific Antigen / metabolism. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18367123.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


6. Tang M, Ogawa K, Asamoto M, Hokaiwado N, Seeni A, Suzuki S, Takahashi S, Tanaka T, Ichikawa K, Shirai T: Protective effects of citrus nobiletin and auraptene in transgenic rats developing adenocarcinoma of the prostate (TRAP) and human prostate carcinoma cells. Cancer Sci; 2007 Apr;98(4):471-7
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protective effects of citrus nobiletin and auraptene in transgenic rats developing adenocarcinoma of the prostate (TRAP) and human prostate carcinoma cells.
  • We here investigated the influence of nobiletin and auraptene on prostate carcinogenesis using transgenic rats developing adenocarcinoma of the prostate (TRAP) bearing the SV40 T antigen transgene under control of the probasin promoter and human prostate cancer cells.
  • The body and relative prostate weights and serum testosterone levels did not differ among the groups.
  • Since all animals developed prostate carcinomas, these were semiquantitatively measured and expressed as relative areas of prostate epithelial cells.
  • Nobiletin caused significant reduction in the ventral (P<0.01), lateral (P<0.001) and dorsal (P<0.05) prostate lobes, while decreasing high grade lesions (P<0.05) in the ventral and lateral lobes.
  • Feeding of auraptene also effectively reduced the epithelial component (P<0.05) and high grade lesions (P<0.05), in the lateral prostate.
  • A further experiment demonstrated that growth of androgen sensitive LNCaP and androgen insensitive DU145 and PC3 human prostate cancer cells, was suppressed by both nobiletin and to a lesser extent auraptene in a dose-dependent manner, with significant increase in apoptosis.
  • In conclusion, these compounds, particularly nobiletin, may be valuable for prostate cancer prevention.
  • [MeSH-major] Adenocarcinoma / prevention & control. Antioxidants / pharmacology. Coumarins / pharmacology. Flavones / pharmacology. Prostatic Neoplasms / prevention & control. Protective Agents / pharmacology

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17284254.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Coumarins; 0 / Flavones; 0 / Protective Agents; 0 / Vegetable Proteins; 495-02-3 / aurapten; D65ILJ7WLY / nobiletin
  •  go-up   go-down


7. Lim TK, Teo C, Giron DM, Chong YL, Cheng C, Tan PH: Thyroid transcription factor-1 may be expressed in ductal adenocarcinoma of the prostate:a potential pitfall. J Clin Pathol; 2007 Aug;60(8):941-3
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid transcription factor-1 may be expressed in ductal adenocarcinoma of the prostate:a potential pitfall.
  • [MeSH-major] Carcinoma, Ductal / immunology. Nuclear Proteins / analysis. Prostatic Neoplasms / immunology. Transcription Factors / analysis
  • [MeSH-minor] Aged. Humans. Immunohistochemistry / methods. Male. Prostate / immunology. Thyroid Gland / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Mar;13(3):238-42 [10757334.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):248-53 [17210521.001]
  • [Cites] Arch Pathol Lab Med. 2001 Feb;125(2):228-31 [11175640.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):815-9 [11395561.001]
  • [Cites] Virchows Arch. 2002 Apr;440(4):353-61 [11956814.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):193-5 [12562233.001]
  • [Cites] Am J Clin Pathol. 2004 Mar;121(3):343-9 [15023038.001]
  • [Cites] Histopathology. 2004 Aug;45(2):125-34 [15279630.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1111-3 [15452173.001]
  • [Cites] Mod Pathol. 1996 Apr;9(4):445-52 [8729987.001]
  • [Cites] Endocrinology. 1998 Jun;139(6):3014-7 [9607813.001]
  • [Cites] Thyroid. 2005 May;15(5):422-6 [15929662.001]
  • [Cites] J Pathol. 2005 Aug;206(4):383-7 [15912575.001]
  • [Cites] Ann Diagn Pathol. 2005 Aug;9(4):189-92 [16084450.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1371-6 [15861215.001]
  • [Cites] Am J Clin Pathol. 2006 Apr;125(4):519-25 [16627262.001]
  • [Cites] Histopathology. 2006 May;48(6):764-5 [16681695.001]
  • [Cites] Am J Surg Pathol. 2006 Jun;30(6):705-12 [16723847.001]
  • [Cites] J Clin Pathol. 2006 Jun;59(6):663-4 [16731609.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1217-23 [10976695.001]
  • (PMID = 17660340.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  • [Other-IDs] NLM/ PMC1994507
  •  go-up   go-down


8. Segawa N, Inamoto T, Ibuki N, Mizutani Y, Azuma H, Tsuji M, Katsuoka Y: [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment : a case report]. Hinyokika Kiyo; 2010 Jan;56(1):49-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment : a case report].
  • A case of neuroendocrine (NE) differentiated prostate cancer is reported herein, which was progressed with NE differentiation during hormonal treatment in adenocarcinoma of the prostate.
  • A 65-year-old man was admitted to our department with increased serum prostate specific antigen (PSA) (150 ng/ml).
  • A prostate biopsy was performed and histological examinations indicated poorly differentiated adenocarcinoma with a Gleason score of 5 + 4 = 9.
  • Computed tomography (CT) demonstrated enlargement of the prostate and swelling of multiple pelvic lymph nodes.
  • His condition worsened rapidly and he died at 8 months after definite diagnosis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Agents, Hormonal / therapeutic use. Leuprolide / therapeutic use. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Cell Differentiation. Humans. Male. Phosphopyruvate Hydratase / analysis. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20104011.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; EC 3.4.21.77 / Prostate-Specific Antigen; EC 4.2.1.11 / Phosphopyruvate Hydratase; EFY6W0M8TG / Leuprolide
  • [Number-of-references] 26
  •  go-up   go-down


9. Sheridan T, Herawi M, Epstein JI, Illei PB: The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Am J Surg Pathol; 2007 Sep;31(9):1351-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
  • BACKGROUND: Adenocarcinoma of the prostate can present as metastatic carcinoma with no known primary.
  • Prostatic origin can be confirmed in most of these cases by immunohistochemistry for prostate-specific antigen (PSA) and prostate-specific acid phosphatase.
  • In a small subset of high-grade prostate carcinomas, both markers are negative and therefore are not helpful for confirming prostatic origin.
  • Recently, novel marker proteins that are preferentially expressed in prostate tissue were identified.
  • It is expressed in both benign and neoplastic prostate tissues, but not in any other normal or malignant tissue examined to date.
  • Owing to its apparent specificity, prostein may be a good marker to demonstrate prostatic origin in metastatic prostate cancer.
  • The tissue microarray contains 78 cases of metastatic prostatic adenocarcinoma, 20 cases of primary prostatic adenocarcinoma, and 20 cases of benign prostate tissue from the peripheral zone as well as samples of benign brain, pancreas, kidney, thyroid, testis, skeletal muscle, and fibroconnective tissue.
  • RESULTS: Similar staining (intensity and extent) was identified for both markers in the majority of metastatic tumors (11 distant sites, 42 pelvic lymph nodes), in all 20 primary tumors and in all benign prostate and nonprostate tissues.
  • In summary, 67 of the 69 cases (97%) of metastatic prostate carcinomas were PSA positive, whereas 68 of the 69 cases showed at least focal weak reactivity for P501S (99%).
  • CONCLUSIONS: Immunohistochemistry for P501S is a sensitive and highly specific marker for identifying prostate tissue.
  • The large majority of metastatic prostatic adenocarcinomas are P501S positive (99%).
  • A small subset of metastatic prostatic adenocarcinoma shows significant differences in staining intensity and extent for PSA and P501S and, therefore, combined use of these markers may result in increased sensitivity for detecting prostatic origin.
  • [MeSH-major] Adenocarcinoma / diagnosis. Membrane Proteins / analysis. Neoplasms, Unknown Primary / diagnosis. Prostate-Specific Antigen / analysis. Prostatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721190.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA58236
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / prostein; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


10. Boland PM, Dhillon RS, Goldstein SD, O'hara BJ, Kastenberg DM: Adenocarcinoma of the prostate presenting as an obstructing rectal mass. Dig Dis Sci; 2007 Oct;52(10):2800-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the prostate presenting as an obstructing rectal mass.
  • [MeSH-major] Adenocarcinoma / secondary. Intestinal Obstruction / etiology. Prostatic Neoplasms / complications. Rectal Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy. Colonoscopy. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17443413.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. López-Navarro N, López-Sánchez JC, Pérez-Enríquez JE, Bosch RJ, Herrera E: [Atypical skin metastases of mucinous adenocarcinoma of the prostate with signet ring cells]. Actas Dermosifiliogr; 2009 May;100(4):338-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Atypical skin metastases of mucinous adenocarcinoma of the prostate with signet ring cells].
  • [Transliterated title] Metástasis cutáneas atípicas de adenocarcinoma mucinoso prostático con células en anillo de sello.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Prostatic Neoplasms / pathology. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19463244.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  •  go-up   go-down


12. Navarro M, Ruiz I, Martín G, Cruz JJ: Patient with disseminated intravascular coagulation as the first manifestation of adenocarcinoma of the prostate. Risks of prostatic biopsy. Prostate Cancer Prostatic Dis; 2006;9(2):190-1
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient with disseminated intravascular coagulation as the first manifestation of adenocarcinoma of the prostate. Risks of prostatic biopsy.
  • Disseminated intravascular coagulation (DIC) can be a rare initial manifestation of adenocarcinoma of the prostate.
  • We present a case in which DIC was the symptom leading to the suspicion of a prostatic tumour.
  • The performance of a prostate biopsy in this situation exacerbated the initial coagulation disorder.
  • This case highlights the risks of prostate biopsy in patients with a suspicion of advanced adenocarcinoma of the prostate.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biopsy, Needle / adverse effects. Disseminated Intravascular Coagulation / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Fatal Outcome. Humans. Male. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16331297.001).
  • [ISSN] 1365-7852
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Lee WR, DeSilvio M, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H: A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019. Int J Radiat Oncol Biol Phys; 2006 Mar 1;64(3):804-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019.
  • Late genitourinary toxicity was graded according to the Common Toxicity Criteria Version 2.0, and the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late radiation morbidity scoring system was used for all other toxicity.
  • CONCLUSIONS: The acute and late morbidity observed in this multi-institutional, cooperative group study is consistent with previous reports from single institutions with significant prostate brachytherapy experience.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Gastrointestinal Tract / radiation effects. Prostatic Neoplasms / radiotherapy. Radiation Injuries / etiology. Urogenital System / radiation effects

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16289906.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


14. Luu T, Sartor O, Dandade N, Halabi S, Bennett C: Comparability of health-related quality of life (HRQOL), treatment decision making, and treatment satisfaction after PSA recurrence among prostate cancer patients who receive hormone therapy (HT) versus observation (OBS): Results from the COMPARE registry. J Clin Oncol; 2009 May 20;27(15_suppl):5131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparability of health-related quality of life (HRQOL), treatment decision making, and treatment satisfaction after PSA recurrence among prostate cancer patients who receive hormone therapy (HT) versus observation (OBS): Results from the COMPARE registry.
  • METHODS: The Comprehensive Multicenter Prostate Adenocarcinoma Registry (COMPARE) is an observational registry of men with PSA failure.
  • The median time between cancer diagnosis and registry enrollment was 6 years.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964431.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Burger M, Hartmann A, Stoehr R, Hofstaedter F, Kneitz B, Riedmiller H, Wieland WF, Denzinger S: [Organization of data and tissue banks for new prognostic factors in adenocarcinoma of the prostate. An interdisciplinary uropathologic approach]. Urologe A; 2007 Sep;46(9):1094
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Organization of data and tissue banks for new prognostic factors in adenocarcinoma of the prostate. An interdisciplinary uropathologic approach].
  • [Transliterated title] Aufbau von Daten- und Gewebebanken für neue Prognosefaktoren beim Adenokarzinom der Prostata. Ein interdisziplinärer uropathologischer Ansatz.
  • [MeSH-major] Adenocarcinoma / pathology. Databases, Factual. Prostatic Neoplasms / pathology. Tissue Banks / organization & administration
  • [MeSH-minor] Biomarkers, Tumor / genetics. Gene Expression Regulation, Neoplastic / physiology. Humans. Male. Oligonucleotide Array Sequence Analysis. Prognosis. Prostate / pathology. Prostatectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2005 Oct;48(4):546-51 [16046052.001]
  • [Cites] Eur Urol. 2006 Nov;50(5):1102-9; discussion 1109-10 [16413100.001]
  • [Cites] J Mol Med (Berl). 2006 Oct;84(10 ):833-41 [16924473.001]
  • [Cites] Eur Urol. 2004 Dec;46(6):725-30 [15548439.001]
  • [Cites] Int J Cancer. 2005 Feb 10;113(4):619-28 [15472903.001]
  • [Cites] Eur Urol. 2006 Aug;50(2):258-65 [16413660.001]
  • (PMID = 17628773.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Ponz-Sarvisé M, Calvo A, Redrado M, Nguewa PA, Abella L, Catena R, García-Foncillas J, Panizo A, Gil-Bazo I: Inhibitor of differentiation-1 (Id1) characterization in poor-prognosis (PP) human bladder cancer (BCa) primary tumors and matched metastases (MTS) using a new monoclonal antibody (MoAb). J Clin Oncol; 2009 May 20;27(15_suppl):e16119

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitor of differentiation-1 (Id1) characterization in poor-prognosis (PP) human bladder cancer (BCa) primary tumors and matched metastases (MTS) using a new monoclonal antibody (MoAb).
  • : e16119 Background: Id1, involved in cell differentiation, proliferation, tumor angiogenesis and metastasis, has recently showed to mediate lung MTS from breast cancer (PNAS 2007).
  • The expression of Id1 in human cancer has been related to poor prognosis breast, prostate (Gil-Bazo, Amer Soc Clin Oncol GU.
  • 2009) and other non-adenocarcinoma tumors.
  • CONCLUSIONS: For the first time using a MoAb against Id1 and in accord with our previous observations in prostate cancer the selection of PP pts increases tumor cell Id1 exp. from 28 up to 80%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963310.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Osunkoya AO, Nielsen ME, Epstein JI: Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases. Am J Surg Pathol; 2008 Mar;32(3):468-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases.
  • Mucinous adenocarcinoma of the prostate is one of the least common variants of prostate cancer.
  • The prognosis of this variant of prostate cancer remains controversial.
  • Mean patient age at diagnosis was 56 years (range: 44 to 69 y).
  • The mean preoperative prostate-specific antigen (PSA) level was 9.0 ng/mL (range: 1.9 to 34.3 ng/mL).
  • Margins were positive in 4 cases of mucinous adenocarcinoma of the prostate.
  • Only 2 cases had isolated margin positivity in the nonmucinous acinar component of cancer.
  • In 12 cases (25.5%), mucinous adenocarcinoma had established extraprostatic extension (EEPE).
  • Eight cases (17.0%) had isolated EEPE of nonmucinous cancer.
  • The 1 lymph node metastasis contained nonmucinous cancer.
  • The 1 lymph node metastasis contained nonmucinous cancer.
  • Using the Kattan nomogram, the predicted mean 5-year PSA progression-free risk for nonmucinous prostate cancer with the same PSA and postoperative findings as in the current study was 85.4%.
  • This study confirms that mucinous adenocarcinoma of the prostate treated by radical prostatectomy is not more aggressive, and possibly even less aggressive than nonmucinous prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / mortality. Prostatectomy. Prostatic Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300802.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


18. Brock M, Martin W, Sommerer F, Noldus J: [Ductal Adenocarcinoma of the prostate with infiltration of the bladder. Can radical cystectomy and antiandrogen therapy cure the disease?]. Urologe A; 2009 Jul;48(7):770-3
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ductal Adenocarcinoma of the prostate with infiltration of the bladder. Can radical cystectomy and antiandrogen therapy cure the disease?].
  • [Transliterated title] Das duktale Adenokarzinom der Prostata mit Blasenhalsinfiltration. Heilung durch radikale Zystektomie und antiandrogene Therapie?
  • Ductal adenocarcinoma of the prostate is a rare entity.
  • The lack of correlation between the prostate-specific antigen value and the tumor stage, as well as early dissemination, are major differences from acinar cancer.
  • We report the case of a 64-year-old man with ductal prostate cancer who underwent radical cystectomy followed by androgen deprivation therapy.
  • [MeSH-major] Androgen Antagonists / administration & dosage. Carcinoma, Ductal / secondary. Carcinoma, Ductal / therapy. Cystectomy / methods. Prostatic Neoplasms / therapy. Urinary Bladder Neoplasms / secondary. Urinary Bladder Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Clin Pract Urol. 2008 Jan;5(1):55-8 [18185514.001]
  • [Cites] Cancer. 1967 Oct;20(10):1715-22 [4168340.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2118-24 [2004331.001]
  • [Cites] Am J Surg Pathol. 1985 Aug;9(8):595-609 [4091189.001]
  • [Cites] Am J Clin Pathol. 2006 Aug;126(2):302-9 [16891207.001]
  • [Cites] Cancer. 2007 May 15;109(10):2011-5 [17420979.001]
  • [Cites] J Urol. 2005 Dec;174(6):2186-90 [16280761.001]
  • [Cites] Cancer. 1976 May;37(5):2255-62 [130969.001]
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1471-9 [10584700.001]
  • [Cites] Urol Oncol. 2007 Jan-Feb;25(1):53-5 [17208139.001]
  • [Cites] Adv Anat Pathol. 2006 Jan;13(1):57-9 [16462155.001]
  • [Cites] BJU Int. 2008 Nov;102(10):1369-74 [18793296.001]
  • [Cites] Semin Diagn Pathol. 1988 Aug;5(3):301-11 [2845546.001]
  • (PMID = 19352617.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Androgen Antagonists
  •  go-up   go-down


19. Makarov DV, Carter HB: The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate. J Urol; 2006 Dec;176(6 Pt 1):2383-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate.
  • PURPOSE: Prostate specific antigen is the most widely used oncological biomarker in medicine today.
  • Before its implementation as an early diagnostic marker, urologists were limited to prostatic acid phosphatase, digital rectal examination and transrectal ultrasound for the detection of prostate cancer.
  • We review the history of the discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate.
  • MATERIALS AND METHODS: We performed a structured literature review, searching PubMed for papers on the subject of prostate specific antigen limited to humans between the years 1970 to 2005.
  • RESULTS: While the use of prostate specific antigen in evaluating newly diagnosed prostate disease, and followup of men after treatment for prostate disease is accepted practice, prostate specific antigen screening for prostate cancer remains controversial.
  • CONCLUSIONS: In the next decade the results of randomized trials of screening may answer some of the questions posed at the beginning of the prostate specific antigen era.
  • To what extent does prostate specific antigen screening affect prostate cancer mortality and at what cost?
  • [MeSH-major] Adenocarcinoma / history. Prostate-Specific Antigen / history. Prostatic Neoplasms / history

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085105.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


20. Kagan AR, Schulz RJ: Intensity-modulated radiotherapy for adenocarcinoma of the prostate: a point of view. Int J Radiat Oncol Biol Phys; 2005 Jun 1;62(2):454-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiotherapy for adenocarcinoma of the prostate: a point of view.
  • Adenocarcinoma of the prostate (CaP) is treated by surgery or irradiation, or both, with the type of treatment determined largely by local resources and referral patterns.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Prostatic Neoplasms / radiotherapy. Radiotherapy, Conformal / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890587.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Zietman AL: Correction: Inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate. JAMA; 2008 Feb 27;299(8):898-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correction: Inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] JAMA. 2005 Sep 14;294(10):1233-9 [16160131.001]
  • (PMID = 18314431.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


22. Brandon ML, Odom SR, Barone JE, Waxberg JA: Adenocarcinoma of the prostate metastatic to the testis via lymphatic invasion: a case report. Conn Med; 2005 Feb;69(2):69-70
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the prostate metastatic to the testis via lymphatic invasion: a case report.
  • [MeSH-major] Adenocarcinoma / secondary. Prostatic Neoplasms / pathology. Testicular Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15779601.001).
  • [ISSN] 0010-6178
  • [Journal-full-title] Connecticut medicine
  • [ISO-abbreviation] Conn Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Zhu Y, Chen L: Identification and characterization of SP cells in human lung adenocarcinoma SPC-A1 cells. J Clin Oncol; 2009 May 20;27(15_suppl):e22230

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and characterization of SP cells in human lung adenocarcinoma SPC-A1 cells.
  • With an extensive understanding of their biology, a major role for stem cells in the malignant process has been proposed and the existence of cancer stem cells(CSCs) has been confirmed in hematopoietic malignancies, brain cancer, and solid organ malignancies including breast, prostate, colon, and pancreatic cancer.
  • Lung cancer is the leading cause of cancer mortality in most large cities of China.
  • It is possible that lung cancer contains cancer stem cells responsible for its malignancy.
  • The aim of this study is to identify, characterize and enrich the CSC population that drives and maintains lung adenocarcinoma growth and metastasis.
  • METHODS: Side population (SP) cell analysis and sorting were applied to established human lung adenocarcinoma cell line and an attempt to further enrich them by preliminary serum-free culture before fluorescence activated cell sorting(FACS) was done.
  • RESULTS: Lung cancer cells could grow in a serum-free Medium (SFM) as non-adherent spheres similar to neurospheres or mammospheres.
  • Flow cytometric analysis of cell phenotyping showed that SP cells expressed CD133 and CD44, the common cell surface markers of cancer stem cells, while non-SP cells only expressed CD44.
  • CONCLUSIONS: SP cells existed in human lung adenocarcinoma cell lines and they could be further enriched by preliminary serum-free culture before FACS sorting.
  • SP cells possessed the properties of cancer stem cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964107.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Santanam L, He T, Yudelev M, Forman JD, Orton CG, Heuvel FV, Maughan RL, Burmeister J: Intensity modulated neutron radiotherapy for the treatment of adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys; 2007 Aug 1;68(5):1546-56
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity modulated neutron radiotherapy for the treatment of adenocarcinoma of the prostate.
  • PURPOSE: This study investigates the enhanced conformality of neutron dose distributions obtainable through the application of intensity modulated neutron radiotherapy (IMNRT) to the treatment of prostate adenocarcinoma.
  • The IMNRT plans were created retrospectively for 5 patients previously treated for prostate adenocarcinoma using fast neutron therapy (FNT), and a comparison of these plans is presented.
  • RESULTS: Plans were normalized such that the IMNRT DVHs for prostate and seminal vesicles were nearly identical to those for conventional FNT plans.
  • The IMNRT technique provides a substantial reduction in normal tissue dose in the treatment of prostate cancer.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Algorithms. Neutrons / therapeutic use. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17674984.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Sanati S, Watson MA, Salavaggione AL, Humphrey PA: Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate. Mod Pathol; 2009 Oct;22(10):1273-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate.
  • Ductal adenocarcinoma is an uncommon variant of prostatic adenocarcinoma with a generally more aggressive clinical course than usual acinar adenocarcinoma.
  • The aim of this investigation was to evaluate the relatedness of ductal versus acinar prostatic adenocarcinoma by comparative gene expression profiling.
  • Archived, de-identified, snap frozen tumor tissue from 5 ductal adenocarcinomas, 3 mixed ductal-acinar adenocarcinomas, and 11 acinar adenocarcinomas cases were analyzed.
  • Overexpression of prolactin receptor protein in ductal versus acinar adenocarcinoma was confirmed by immunohistochemistry in an independent set of tumors.
  • We conclude that ductal and acinar adenocarcinomas of the prostate are strikingly similar at the level of gene expression.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19633648.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Prolactin
  •  go-up   go-down


26. Herawi M, De Marzo AM, Kristiansen G, Epstein JI: Expression of CDX2 in benign tissue and adenocarcinoma of the prostate. Hum Pathol; 2007 Jan;38(1):72-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CDX2 in benign tissue and adenocarcinoma of the prostate.
  • We have recently seen 2 cases of prostatic adenocarcinoma (PCa) on needle biopsies with diffuse strong nuclear staining for CDX2 sent for consultation.
  • One case was a prostatic duct adenocarcinoma in a man with a prostate-specific antigen (PSA) value of 327 ng/mL, and the other was a PCa with a Gleason score (GS) of 4 + 4 = 8 in a man with a PSA value of 15 ng/mL.
  • An adenocarcinoma with GS 3 + 3 = 6 from the contralateral side did not express CDX2.
  • Three slides of TMAs were used to stain 708 tissue samples (0.6 mm in diameter) containing either benign or malignant prostate tissue, as well as control tissues from various anatomical sites including colon.
  • In total, 195 samples of primary PCa with GS of 6 (n = 41), 7 (n = 21), and 8 (n = 8); 195 samples of benign prostate tissue; and 185 samples of metastatic PCa were studied.
  • Focal moderate positive staining was seen in benign prostate tissue in 7 (11.7%) of 60 radical prostatectomy specimens.
  • CDX2 may uncommonly be focally expressed in benign prostatic glands.
  • Positive CDX2 staining in high-grade prostate cancer (ductal, cribriform, and solid) may be confused with secondary carcinoma of colonic origin.
  • Routine histopathology, positive PSA immunostaining, and clinical findings can help confirm the correct diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Homeodomain Proteins / biosynthesis. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Humans. Immunohistochemistry. Male. Middle Aged. Prostate-Specific Antigen / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949907.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA58236
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / Homeodomain Proteins; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


27. Lane BR, Magi-Galluzzi C, Reuther AM, Levin HS, Zhou M, Klein EA: Mucinous adenocarcinoma of the prostate does not confer poor prognosis. Urology; 2006 Oct;68(4):825-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma of the prostate does not confer poor prognosis.
  • OBJECTIVES: To report a series of patients with mucinous (colloid) adenocarcinoma (MC) at prostatectomy who were treated at a single institution from 1987 to 2005.
  • MC is a rare form of prostate cancer reported in some cases to have a more aggressive clinical course than conventional adenocarcinoma (AC).
  • Each case was reviewed again by a single pathologist who confirmed the diagnosis of MC in 14 patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17070361.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Mackler NJ, Dunn RL, Hellerstedt B, Cooney KA, Fardig J, Olson K, Pienta KJ, Smith DC: Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. Cancer; 2006 Jun 15;106(12):2617-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
  • BACKGROUND: The primary objective of the current study was to identify the tolerable dose level of oral vinorelbine when given in combination with estramustine to men with hormone-refractory prostate cancer (HRPC).
  • The secondary objectives were to describe the toxicities of the combined regimen in patients with HRPC and to estimate the efficacy of oral vinorelbine in combination with estramustine based on the prostate-specific antigen (PSA) response.
  • The combination appears to have modest activity in men with advanced prostate cancer.
  • More active regimens are needed to further evaluate the utility of this clinical trial design in patients with prostate cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Estramustine / adverse effects. Prostatic Neoplasms / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Administration, Oral. Aged. Aged, 80 and over. Confidence Intervals. Disease Progression. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Drug Therapy, Combination. Humans. Male. Maximum Tolerated Dose. Middle Aged. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16691618.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2P30 CA 46592-14
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 35LT29625A / Estramustine; 5V9KLZ54CY / Vinblastine; EC 3.4.21.77 / Prostate-Specific Antigen; Q6C979R91Y / vinorelbine
  •  go-up   go-down


29. Gong Y, Caraway N, Stewart J, Staerkel G: Metastatic ductal adenocarcinoma of the prostate: cytologic features and clinical findings. Am J Clin Pathol; 2006 Aug;126(2):302-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic ductal adenocarcinoma of the prostate: cytologic features and clinical findings.
  • We retrospectively reviewed the cytologic features of metastatic prostatic ductal carcinoma (PDC) in 23 cases, clinical manifestations, and clinical outcomes.
  • A determination of a prostatic origin of a metastatic PDC, based on cytomorphologic features alone, could be difficult.
  • Immunostaining for prostate-specific antigen and prostatic acid phosphatase proved helpful in determining a definitive diagnosis.
  • The correlation with clinical and radiologic findings, a high index of suspicion, and the use of immunoperoxidase studies are important in making an accurate diagnosis.
  • [MeSH-major] Carcinoma, Ductal / secondary. Prostatic Neoplasms / pathology
  • [MeSH-minor] Acid Phosphatase. Aged. Biomarkers, Tumor / analysis. Biopsy, Needle. Humans. Immunoenzyme Techniques. Male. Middle Aged. Prognosis. Prostate-Specific Antigen / analysis. Protein Tyrosine Phosphatases / analysis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16891207.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


30. Nguyen TD, Poortmans PM, van der Hulst M, Studer G, Pigois E, Collen TD, Belkacemi Y, Beckendorf V, Miralbell R, Scandolaro L, Soete G, Villa S, Gez E, Thomas O, Krengli M, Jovenin N: The curative role of radiotherapy in adenocarcinoma of the prostate in patients under 55 years of age: a rare cancer network retrospective study. Radiother Oncol; 2005 Dec;77(3):286-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The curative role of radiotherapy in adenocarcinoma of the prostate in patients under 55 years of age: a rare cancer network retrospective study.
  • To determine whether radiation therapy could be an acceptable alternative to surgery in young patients with adenocarcinoma of the prostate, we analysed the outcome of 39 patients aged under 55 with organ confined tumours who received external radiation therapy in a curative intent.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Neoplasm Recurrence, Local / prevention & control. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16307812.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


31. Fleischmann AM, Waser B, Reubi JC: Gastrin-releasing peptide receptors in the tumor vascular bed of various human cancers: high incidence in urinary tract cancers. J Clin Oncol; 2009 May 20;27(15_suppl):e14575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14575 Background: Tumoral Gastrin-releasing peptide (GRP) receptors are potential targets for diagnosis and therapy using radiolabeled or cytotoxic GRP analogs.
  • GRP-receptor overexpression has been detected in cancer cells and, more recently, also in the vascular bed of selected tumors.
  • More information on vascular GRP-receptors in cancer is required to asses their potential for vascular targeting applications.
  • METHODS: Frequent human cancers from the breast (n=134), lung (n=57), prostate (n=50), kidney (n=32), colon (n=46), urinary tract (n=26) and biliary tract (n=23) were analyzed using in vitro GRP-receptor autoradiography on tissue sections with the <sup>125</sup>I-[Tyr<sup>4</sup>]-bombesin radioligand and/or the universal radioligand <sup>125</sup>I-[D-Tyr<sup>6</sup>, ß-Ala<sup>11</sup>, Phe<sup>13</sup>, Nle<sup>14</sup>]-bombesin(6-14).
  • RESULTS: Prevalence of vascular GRP-receptors is variable, ranging from 13% (prostate cancer) to 92% (urinary tract cancer).
  • Different tumor-types within a given site may have divergent prevalence of vascular GRP-receptors (e.g. lung: small cell cancer: 0%; adenocarcinoma: 59%; squamous carcinoma: 83%).
  • Also the vascular score varies widely, with highest score in urinary tract cancer (1.69), moderate scores in lung (0.91), colon (0.88), kidney (0.84) and biliary tract (0.69) cancers and low scores in breast (0.39) and prostate (0.14) cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963648.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Lujan M, Cardona AF, Yepes A, Carrasco-Chaumel E, Reveiz L, Otero JM: Myelophthisis in solid tumors: Old aspects, new concepts (ONCOLGroup study). J Clin Oncol; 2009 May 20;27(15_suppl):e20672

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-seven pts (30%) had breast cancer, pathology followed by primary unknown tumours (21%), rabdomiosarcoma (10%), prostate adenocarcinoma (10%), gastric carcinoma (7%) and others (22%).
  • Forty-three pts received chemotherapy following the diagnosis of medullar infiltration, and normal leukocyte count was being seen in 40% of them after such treatment.
  • Nine episodes of febrile neutropenia were found; median overall survival (OS) following the diagnosis of neoplasia and myelophtisis were 13.8 months and 2.2 months respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961689.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Sturgis CD, Box M, D'Costa R, Forgue B, McGuire MS, Dieterich M: Ancillary alpha-methylacyl-CoA racemase immunocytochemistry in the diagnosis of adenocarcinoma of the prostate in urinary cytology: a case report. Acta Cytol; 2006 May-Jun;50(3):335-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ancillary alpha-methylacyl-CoA racemase immunocytochemistry in the diagnosis of adenocarcinoma of the prostate in urinary cytology: a case report.
  • BACKGROUND: Alpha-methylacyl-coA racemase (AMACR) was recently shown to be a sensitive immunohistochemical marker for substantiating a diagnosis of adenocarcinoma of the prostate.
  • This area was biopsied, and histologic studies of the tissue chips demonstrated underlying prostatic adenocarcinoma directly invading the urothelium.
  • We used AMACR immunoreactivity on a retrospectively studied, catheterized urine slide to confirm the diagnosis.
  • CONCLUSION: This case suggests that combined cytomorphology and immunocytochemisty for AMACR may allow an accurate identification of cells of prostatic adenocarcinoma when cytomorphologic studies or the clinical history raises the differential diagnosis of prostate cancer presenting with exfoliation of malignant cells into the urine.
  • [MeSH-major] Adenocarcinoma / diagnosis. Prostatic Neoplasms / diagnosis. Racemases and Epimerases / analysis. Urine / cytology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Prostate-Specific Antigen / analysis. Urinary Catheterization. Urologic Neoplasms / diagnosis. Urologic Neoplasms / urine

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780032.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


34. Jonsson E, Sigbjarnarson HP, Tomasson J, Benediktsdottir KR, Tryggvadottir L, Hrafnkelsson J, Olafsdottir EJ, Tulinius H, Jonasson JG: Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987. Scand J Urol Nephrol; 2006;40(4):265-71
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
  • OBJECTIVE: To investigate adenocarcinoma of the prostate in a single population with an extended follow-up period.
  • MATERIAL AND METHODS: Using the Icelandic Cancer Registry, we identified all Icelandic men diagnosed with prostate cancer between 1983 and 1987.
  • A critical evaluation was made of the accuracy of the death certificates regarding prostate cancer.
  • RESULTS: A total of 414 men were diagnosed with adenocarcinoma of the prostate.
  • Of these, 370 were alive at the time of diagnosis and stage could be determined.
  • The mean age at diagnosis was 74.4 years (range 53-94 years).
  • A total of 334 patients died during the follow-up period, of whom 168 (50%) died of prostate cancer.
  • Prostate cancer-specific survival at 10 and 15 years was 100% and 90.6%, respectively for focal incidental cancer; 73.1% and 60.8% for men with localized disease; 23.4% and 11.7% for local advanced disease; and 6.81% and 5.45% for metastatic disease.
  • A Cox multivariate analysis showed age, stage and Gleason score to be independent predictors of prostate cancer death.
  • Death certificates were judged to be accurate with regard to prostate cancer in nearly all instances (96%).
  • CONCLUSIONS: During an extended follow-up period, half of all patients with prostate cancer died from the disease.
  • However, a higher stage and grade were associated with substantial prostate cancer mortality.
  • Death certificates were accurate as far as prostate cancer was concerned.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16916765.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  •  go-up   go-down


35. Aydin H, Zhang J, Samaratunga H, Tan N, Magi-Galluzzi C, Klein E, Jones JS, Zhou M: Ductal adenocarcinoma of the prostate diagnosed on transurethral biopsy or resection is not always indicative of aggressive disease: implications for clinical management. BJU Int; 2010 Feb;105(4):476-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal adenocarcinoma of the prostate diagnosed on transurethral biopsy or resection is not always indicative of aggressive disease: implications for clinical management.
  • OBJECTIVE: To report the clinicopathological characteristics of 23 cases of ductal adenocarcinoma of the prostate (DCP) and discuss the implications for clinical management, as DCP is considered an aggressive subtype of prostate adenocarcinoma (PA).
  • PATIENTS AND METHODS: The presence of DCP in transrectal ultrasonography-guided prostate biopsy (TRUSB) is associated with adverse pathological findings at radical prostatectomy (RP) and clinical outcomes, and the significance of detecting DCP initially in transurethral biopsy (UB) or transurethral resection (TURP) in the present era of screening with prostate-specific antigen (PSA) is unclear.
  • Two (11%) patients had no residual cancer, one on RP and the other on two repeat TURPs.
  • We recommend that patients with a diagnosis of DCP on UB or TURP undergo follow-up TURP and TRUSB before radical surgery is offered.
  • [MeSH-major] Carcinoma, Ductal / pathology. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Humans. Male. Middle Aged. Prognosis. Prostate-Specific Antigen / blood. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19709071.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


36. D'Amico AV, Denham JW, Bolla M, Collette L, Lamb DS, Tai KH, Steigler A, Chen MH: Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate. Cancer; 2007 May 15;109(10):2004-10
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate.
  • BACKGROUND: The study evaluated whether the use of 3 years as compared with 6 months of androgen suppression therapy (AST) combined with external beam radiation therapy (RT) in the treatment of high-risk prostate cancer was associated with prolonged survival in advanced age men.
  • METHODS: A pooled analysis of 311 men enrolled in 3 prospective randomized trials between 1987 and 2000 who received 6 months or 3 years of AST and RT for locally advanced or high-grade localized adenocarcinoma of the prostate comprised the study cohort.
  • CONCLUSIONS: After adjusting for known prognostic factors, the treatment of node-negative, high-risk prostate cancer using 3 years as compared with 6 months of AST with RT was not associated with prolonged survival in men of advanced age.
  • The European Organization for Research and Treatment of Cancer randomized trial will help answer whether unknown confounding factors affected the results of the study.
  • [MeSH-major] Adenocarcinoma / therapy. Androgen Antagonists / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Prostatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society
  • [CommentIn] Nat Clin Pract Urol. 2007 Nov;4(11):588-9 [17876356.001]
  • (PMID = 17397033.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


37. Duan W, Gabril MY, Moussa M, Chan FL, Sakai H, Fong G, Xuan JW: Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model. Oncogene; 2005 Feb 24;24(9):1510-24
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model.
  • Prostate cancer (CaP) is the most common cancer in adult men in North America.
  • Since there is no naturally occurring prostate cancer in the mouse, preclinical studies stipulate for the establishment of a genetically manipulated mouse CaP model with features close to the human situation.
  • In view of the limitations of transgenic technique-derived CaP models, herein we report the first application of knockin technology to establish a new mouse adenocarcinoma prostate model (PSP-KIMAP) by targeting of SV40 Tag to a prostate tissue-specific gene, PSP94 (prostate secretory protein of 94 amino acids).
  • In order to demonstrate its novelty, we compared KIMAP to a PSP94 gene-directed transgenic mouse adenocarcinoma of the prostate (PSP-TGMAP) model.
  • The CaP development of the PSP-KIMAP mice started almost immediately after puberty at 10 weeks of age from mouse prostatic intraepithelial neoplasia (mPIN) with microinvasion to well-differentiated CaP, and demonstrated a close-to-human kinetics of prolonged tumor growth and a predominance of well and moderately differentiated tumors.
  • The invasive nature of KIMAP model was demonstrated by multitissue metastases (lymph node, lung and liver etc) and also by immunohistochemical study of multiple invasive prostate tumor markers.
  • These features include the high stability of both phenotype and genotype, highly synchronous prostate cancer development, high and precise prostate tissue targeting and with no founder line variation.
  • The differences between the two CaP models were attributed to the introduction of a single endogenous knockin mutation, resulting in a CaP model self-regulated and controlled by a prostate gene promoter/enhancer of PSP94.
  • [MeSH-major] Adenocarcinoma / genetics. Antigens, Polyomavirus Transforming / genetics. Prostatic Neoplasms / genetics. Simian virus 40 / genetics
  • [MeSH-minor] Animals. Basement Membrane / pathology. Exons / genetics. Male. Mice. Mice, Transgenic. Neoplasm Metastasis. Orchiectomy. Prostatic Secretory Proteins / genetics


38. Anscher MS, Clough R, Robertson CN, Prosnitz LR, Dahm P, Walther P, Donatucci CF, Albala DM, Febbo P, George DJ, Sun L, Moul JW: Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. Prostate Cancer Prostatic Dis; 2006;9(3):254-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate.
  • Between 1970 and 1983, 159 patients underwent RP for newly diagnosed adenocarcinoma of the prostate and were found to have positive surgical margins, extracapsular extension and/or seminal vesicle invasion.
  • The RT group generally received 45-50 Gy to the whole pelvis, then a boost to the prostate bed (total dose of 55-65 Gy).
  • In contrast to recurrences, nearly half of deaths from prostate cancer occurred more than 10 years after treatment.
  • Deaths from prostate cancer represented 55% of all deaths in these patients.
  • Despite its long natural history, death from prostate cancer was the most common cause of mortality in this population with locally advanced tumors, reflecting the need for more effective therapy.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16880828.001).
  • [ISSN] 1365-7852
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


39. Uchida T, Illing RO, Cathcart PJ, Emberton M: To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int; 2006 Sep;98(3):537-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate?
  • OBJECTIVE: To explore the association between the prostate-specific antigen (PSA) nadir after transrectal high-intensity focused ultrasound (HIFU) therapy for organ-confined prostate cancer and subsequent treatment failure, as defined by the presence of residual disease at biopsy 6 months after treatment.
  • PATIENTS AND METHODS: Between January 1999 and January 2005, 115 patients in a Japanese hospital were treated using a transrectal HIFU system (Sonablate, Focus Surgery, IN, USA) for presumed localized adenocarcinoma of the prostate.
  • The PSA level was measured at 2-monthly intervals and all patients had a transrectal prostate biopsy taken at 6 months.
  • In addition, the PSA nadir was strongly associated with both preoperative PSA level and residual prostate volume.
  • These data can be used to predict the risk of residual disease in patients with prostate cancer undergoing HIFU therapy.
  • [MeSH-major] Adenocarcinoma / therapy. Prostate-Specific Antigen / metabolism. Prostatic Neoplasms / therapy. Ultrasound, High-Intensity Focused, Transrectal / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16925749.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


40. Sonpavde G, Frolov A, Macdonell V, Hayes TG, Mims MP, Ayala GE, Wheeler TM, Thompson TC, Ittman MM, Kadmon D: Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer (PCa) followed by radical prostatectomy (RP). J Clin Oncol; 2009 May 20;27(15_suppl):5127

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer (PCa) followed by radical prostatectomy (RP).
  • Histological evidence of adenocarcinoma of the prostate was required with clinical stage T<sub>1c</sub> or T<sub>2a</sub> with Gleason 8-10 disease, or clinical stage T<sub>2b</sub>-T<sub>2c</sub> with Gleason grade 7 and PSA of >10 ng/mL, or clinical stage T<sub>3</sub>.
  • Upregulation of apoptosis, proliferation and phosphorylated (p)-Akt have been previously reported in a subset of patients by our group (Ayala GE et al, Clin Cancer Res. 2008;14:7511-8).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964403.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Greenlee JE, Clawson SA, Hill KE, Dechet CB, Carlson NG: Antineuronal autoantibodies in paraneoplastic cerebellar degeneration associated with adenocarcinoma of the prostate. J Neurol Sci; 2010 Apr 15;291(1-2):74-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antineuronal autoantibodies in paraneoplastic cerebellar degeneration associated with adenocarcinoma of the prostate.
  • Paraneoplastic neurological syndromes are unusual in prostatic cancer, and paraneoplastic cerebellar degeneration associated with adenocarcinoma of the prostate is rare.
  • Here we report a 68year old man who developed progressive ataxia in the setting of stage D2 adenocarcinoma of the prostate and whose MRI showed cerebellar atrophy.
  • Sera from neurologically normal patients with adenocarcinoma of the prostate did not contain this antibody, and the patient's serum did not react with normal prostate or with prostatic adenocarcinomas from other individuals.
  • Prostatic adenocarcinoma may occasionally be accompanied by development of anticerebellar antibodies.
  • Adenocarcinoma of the prostate should be considered as a possible underlying malignancy in older males with unexplained progressive cerebellar degeneration.
  • [MeSH-major] Adenocarcinoma / immunology. Autoantibodies / blood. Brain / immunology. Neurons / immunology. Paraneoplastic Cerebellar Degeneration / immunology. Prostatic Neoplasms / immunology

  • Genetic Alliance. consumer health - Cerebellar Degeneration.
  • Genetic Alliance. consumer health - Paraneoplastic cerebellar degeneration.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier B.V.
  • (PMID = 20089262.001).
  • [ISSN] 1878-5883
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Autoantibodies
  •  go-up   go-down


42. Veshapidze N, Alibegashvili M, Gabunia N, Chigogidze T, Managadze L: Characteristics of morphological change in erythrocytes during metaststic adenocarcinoma of the prostate before and after castration. Georgian Med News; 2009 Jul-Aug;(172-173):10-3
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of morphological change in erythrocytes during metaststic adenocarcinoma of the prostate before and after castration.
  • For the experimental research we used a blood serum and erythrocytes of 15 men with metastasized adenocarcinoma before castration and a blood serum and erythrocytes of 15 men in 6 months after castration, also a blood serum and erythrocytes of practically healthy men.
  • Deep morphological changes of erythrocytes were observed in peripheral blood during metastasized adenocarcinoma of prostate gland before and after castration.
  • [MeSH-major] Adenocarcinoma / blood. Erythrocytes / pathology. Prostatic Neoplasms / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19644180.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


43. Larrousse C, Brasseur P, Sukkarieh F: [Port-site metastasis following laparoscopic radical prostatectomy for mucinous adenocarcinoma of the prostate]. J Radiol; 2005 Mar;86(3):337-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Port-site metastasis following laparoscopic radical prostatectomy for mucinous adenocarcinoma of the prostate].
  • [Transliterated title] Métastase orificielle après prostatectomie radicale coelioscopique pour un adénocarcinome mucineux de la prostate.
  • A 52-year-old man underwent laparoscopic radical prostatectomy for mucinous adenocarcinoma.
  • [MeSH-major] Abdominal Neoplasms / secondary. Abdominal Wall. Adenocarcinoma, Mucinous / secondary. Laparoscopy / adverse effects. Neoplasm Seeding. Prostatectomy / methods. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908875.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


44. Christian JD, Lamm TC, Morrow JF, Bostwick DG: Corpora amylacea in adenocarcinoma of the prostate: incidence and histology within needle core biopsies. Mod Pathol; 2005 Jan;18(1):36-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corpora amylacea in adenocarcinoma of the prostate: incidence and histology within needle core biopsies.
  • Corpora amylacea in the prostate are a frequent finding in benign acini, but are only rarely observed in adenocarcinoma.
  • Among 5130 cases of adenocarcinoma (34% of 15,279 total needle biopsy cases), we identified 19 (31 biopsy specimens) with corpora amylacea within cancerous acini (0.4% incidence).
  • Our results indicate that the incidence of corpora amylacea in adenocarcinoma is low, but the presence of such inclusions cannot be used to exclude malignancy.
  • [MeSH-major] Adenocarcinoma / complications. Prostate / pathology. Prostatic Neoplasms / complications
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Humans. Incidence. Male. Middle Aged. Prostatic Diseases / complications. Prostatic Diseases / epidemiology. Prostatic Diseases / pathology. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15309020.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Parwani AV, Herawi M, Epstein JI: Pleomorphic giant cell adenocarcinoma of the prostate: report of 6 cases. Am J Surg Pathol; 2006 Oct;30(10):1254-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic giant cell adenocarcinoma of the prostate: report of 6 cases.
  • However, only a few cases have been described among prostatic carcinomas with only 1 on diagnostic biopsy material.
  • The diagnosis was made on needle biopsy (n=3), urethral biopsy (n=1), transurethral resection (n=1), or radical prostatectomy (n=1).
  • In addition to the pleomorphic giant cell component, multiple coexistent histologic components were seen including Gleason score 9 conventional prostate cancer (n=6), small cell carcinoma (n=1), squamous carcinoma (n=1), and prominent ductal adenocarcinoma differentiation with intraductal spread (n=1).
  • Immunohistochemically, 4 cases were for negative for prostate-specific antigen in the giant cells, 1 had 5% staining, and the other had 50% positivity in the giant cells.
  • Staining for prostate-specific antigen in the conventional prostate carcinoma component was 1%, 5%, 20%, 50%, 100%, and 100%.
  • Two cases had a history of conventional prostate cancer 4 years before the giant cell component, 1 treated with Lupron and the other with radiation.
  • Follow-up after diagnosis of the giant cell component: Case 1: dead in 1 year of disease; Case 2: progressive metastases in 2 years; Case 3: alive at 1 year with disease; Case 4: large perineal recurrence after brachytherapy at 3 years; Case 5: radical prostatectomy with extraprostatic extension and seminal vesicle invasion; and Case 6: alive at 3 months, free of disease.
  • Conventional prostate cancer, even when very high grade, typically consists of cells with relatively uniform nuclei.
  • Our study expands the histology described in prostate cancer to include in very rare cases with prominent pleomorphism and bizarre giant cells.
  • [MeSH-major] Adenocarcinoma / pathology. Giant Cells / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Humans. Male. Middle Aged. Prostate-Specific Antigen / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001156.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


46. Veestraeten D: An alternative approach to modelling relapse in cancer with an application to adenocarcinoma of the prostate. Math Biosci; 2006 Jan;199(1):38-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An alternative approach to modelling relapse in cancer with an application to adenocarcinoma of the prostate.
  • This paper proposes an alternative approach to modelling relapse in cancer.
  • This framework will be exemplified for prostatic cancer by extending the recently proposed stochastic model of Dayananda et al. [P.W.A.
  • Shvartsman, A stochastic model for prostate-specific antigen levels, Math. Biosci.
  • 190 (2004) 113] that focussed on the dynamics of the prostate-specific antigen (PSA) biomarker.
  • [MeSH-major] Adenocarcinoma / pathology. Models, Statistical. Neoplasm Recurrence, Local / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Algorithms. Humans. Male. Prostate-Specific Antigen / blood. Stochastic Processes

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Math Biosci. 2013 Jan;241(1):145-6
  • (PMID = 16364375.001).
  • [ISSN] 0025-5564
  • [Journal-full-title] Mathematical biosciences
  • [ISO-abbreviation] Math Biosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


47. Konski A, Speier W, Hanlon A, Beck JR, Pollack A: Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol; 2007 Aug 20;25(24):3603-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?
  • The specific aim of this study was to examine the cost effectiveness of proton beam radiation compared with current state-of-the art therapy in the treatment of patients with prostate cancer.
  • CONCLUSION: Even when based on the unproven assumption that protons will permit a 10-Gy escalation of prostate dose compared with IMRT photons, proton beam therapy is not cost effective for most patients with prostate cancer using the commonly accepted standard of $50,000/QALY.
  • [MeSH-major] Adenocarcinoma / economics. Adenocarcinoma / radiotherapy. Prostatic Neoplasms / economics. Prostatic Neoplasms / radiotherapy. Protons / therapeutic use. Radiotherapy / economics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Aug 20;25(24):3565-6 [17704400.001]
  • (PMID = 17704408.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 R01 CA101984-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


48. Morgan TM, Welty CJ, Vakar-Lopez F, Lin DW, Wright JL: Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen. J Urol; 2010 Dec;184(6):2303-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen.
  • PURPOSE: The clinical significance of ductal prostatic carcinoma is not well-defined.
  • In a population based cancer registry we identified a large group of patients with ductal carcinoma to characterize the impact of the ductal subtype on presentation and survival in men with prostate cancer.
  • MATERIALS AND METHODS: We used a national cancer registry to identify incident cases of ductal and acinar adenocarcinoma from 1996 to 2006.
  • Prostate specific antigen values were available for 2004 to 2006 and used to assess differences in Gleason grade and serum prostate specific antigen between ductal and acinar cancer cases at diagnosis.
  • Ductal histology was associated with a 30% decrease in geometric mean prostate specific antigen (adjusted coefficient 0.7, 95% CI 0.6-0.8) and more than 2-fold increased odds of prostate specific antigen less than 4.0 ng/ml (OR 2.4, 95% CI 1.4-4.0) independent of other clinicopathological variables.
  • In men with nondistant disease at diagnosis ductal histology was associated with 2.2-fold (CI 1.4-3.5) increased disease specific mortality.
  • CONCLUSIONS: In what is to our knowledge the largest series of this histological subtype ductal cancer cases were more likely to present with advanced stage cancer and lower prostate specific antigen, suggesting that timely disease detection is a significant challenge.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1471-9 [10584700.001]
  • [Cites] BJU Int. 2010 Feb;105(4):476-80 [19709071.001]
  • [Cites] Cancer. 2002 May 15;94(10):2610-7 [12173328.001]
  • [Cites] Cancer. 1967 Oct;20(10):1715-22 [4168340.001]
  • [Cites] Cancer. 1973 Aug;32(2):402-9 [4124700.001]
  • [Cites] J Urol. 1979 Mar;121(3):303-5 [219263.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):111-9 [2416422.001]
  • [Cites] Am J Surg Pathol. 1985 Aug;9(8):595-609 [4091189.001]
  • [Cites] Cancer. 1987 May 15;59(10):1803-9 [3030528.001]
  • [Cites] Prostate. 1987;10(2):123-31 [2436204.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2118-24 [2004331.001]
  • [Cites] Histopathology. 1996 Jul;29(1):11-9 [8818689.001]
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):840-8 [9669346.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1119-23 [9781651.001]
  • [Cites] Am J Surg Pathol. 1999 Jul;23(7):781-5 [10403300.001]
  • [Cites] Am J Clin Pathol. 2006 Aug;126(2):302-9 [16891207.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):198-204 [17171704.001]
  • [Cites] Pathology. 2007 Oct;39(5):476-81 [17886096.001]
  • [Cites] Urol Oncol. 2008 Jul-Aug;26(4):368-71 [18367098.001]
  • [Cites] Cancer. 2009 Jul 1;115(13):2872-80 [19402048.001]
  • [Cites] Hum Pathol. 2010 Feb;41(2):281-5 [20004936.001]
  • [Cites] Am J Clin Pathol. 2002 Apr;117(4):552-7 [11939729.001]
  • (PMID = 20952027.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA009168-30; United States / NCI NIH HHS / CA / T32 CA009168; United States / NCI NIH HHS / CA / T32 CA009168-30
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS294511; NLM/ PMC3111052
  •  go-up   go-down


49. Mazigo HD, Zinga M, Heukelbach J, Rambau P: Case Series of Adenocarcinoma of the Prostate Associated with Schistosoma haematobium Infection in Tanzania. J Glob Infect Dis; 2010 Sep;2(3):307-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case Series of Adenocarcinoma of the Prostate Associated with Schistosoma haematobium Infection in Tanzania.
  • In endemic areas, schistosomiasis has been associated with the pathogenesis of bladder, prostate, colorectal and renal carcinoma.
  • However, the relationship between prostate cancer and schistosomiasis infection remains controversial.
  • Here we present a series of three cases from Tanzania of prostatic adenocarcinoma associated with urinary schistosomiasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20927294.001).
  • [ISSN] 0974-8245
  • [Journal-full-title] Journal of global infectious diseases
  • [ISO-abbreviation] J Glob Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2946689
  • [Keywords] NOTNLM ; Adenocarcinoma / Prostate / Schistosoma haematobium / Schistosomiasis / Tanzania
  •  go-up   go-down


50. Eilers T, Machtens S, Tezval H, Blaue C, Lichtinghagen R, Hagemann J, Jonas U, Serth J: Prospective diagnostic efficiency of biopsy washing DNA GSTP1 island hypermethylation for detection of adenocarcinoma of the prostate. Prostate; 2007 May 15;67(7):757-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective diagnostic efficiency of biopsy washing DNA GSTP1 island hypermethylation for detection of adenocarcinoma of the prostate.
  • METHODS: Biopsies were obtained prospectively from 86 patients suspicious for prostate cancer (CaP).
  • Moreover it is compatible with routine biopsy examination thus permitting further prospective evaluation in CaP diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. DNA, Neoplasm / metabolism. Glutathione S-Transferase pi / metabolism. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor. Biopsy, Needle. Cell Count. DNA Methylation. Gene Expression Regulation, Neoplastic. Humans. Male. Predictive Value of Tests. Promoter Regions, Genetic. Prospective Studies. Prostate / metabolism. Prostate / pathology. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17373715.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi
  •  go-up   go-down


51. Urbanskiĭ AI: [Correlation between size and localization of stage-pT adenocarcinoma of the prostate]. Vopr Onkol; 2006;52(6):649-53
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between size and localization of stage-pT adenocarcinoma of the prostate].
  • According to the data on resected material sampled from 58 cases of radical prostatectomy, a relationship between size of adenocarcinoma and prostate and localization of the main tumor node, on the one hand, and pathological stage (pT) of primary tumor was established.
  • Incidence of pT3 was dependent on tumor volume when adenocarcinoma was in the periphery of the prostate which involved the following relationships between pT, on the one hand, and tumor size and site, on the other: the closer tumor to the gland center, the lower the value of pT.
  • Risk of pT3 appeared to be associated with small size of the prostate.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17338242.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


52. Renzulli JF 2nd, Dooner G, Owens C, Colvin G, Dooner M, Del Tatto M, Goldstein L, Quesenberry P: Microvesicular-mediated gene transfer of prostate tumor markers. J Clin Oncol; 2009 May 20;27(15_suppl):e16076

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microvesicular-mediated gene transfer of prostate tumor markers.
  • Recent work has focused on the potential for cancer vaccines via microvesicles.
  • Our objective is to determine whether there is transfer of genetic or transcriptional factors via microvesicles from human prostate cancer cells to fresh human marrow cells.
  • METHODS: Fresh prostate tissue was harvested from surgical specimens following radical retropubic prostatectomy.
  • Samples were histologically confirmed to contain prostatic adenocarcinoma.
  • Co-cultures were established using a transwell system in which 0.05-0.100 grams of prostate tissue was minced and co-cultured with 1-3 million normal, human donor marrow cells for 2-7 days.
  • Target cells were collected and total RNA was analyzed for prostate-specific gene expression byReal Time RT-PCR.
  • RESULTS: We have observed significant increases in gene expression in marrow cells co-cultured with prostate tumor cells (Gleason grades 6-9).
  • CONCLUSIONS: These studies demonstrate that prostate specific genes are present in fresh human marrow cells after co-culture with tumor tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963050.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Molenaar JP, Baten A, Blokx WA, Hoogendam A: Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate. Eur Urol; 2009 Nov;56(5):874-7; quiz 876
Hazardous Substances Data Bank. BICALUTAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate.
  • We present the case of an 81-yr-old man with a prostatic adenocarcinoma and a metastatic carcinoid.
  • Simultaneous occurrence of hormonally treated adenocarcinoma of the prostate and a carcinoid has been described before.
  • The pathogenesis of this coincidence is largely unclear; however, androgen deprivation therapy might play a key role in neuroendocrine differentiation of adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / therapeutic use. Anilides / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Carcinoid Tumor / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary. Nitriles / therapeutic use. Prostatic Neoplasms / drug therapy. Tosyl Compounds / therapeutic use

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19171417.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Tosyl Compounds; 51110-01-1 / Somatostatin; A0Z3NAU9DP / bicalutamide
  •  go-up   go-down


54. Kang JJ, Eaton MS, Ma Y, Streeter O, Kumar P: Mucosa-associated lymphoid tissue lymphoma and concurrent adenocarcinoma of the prostate. Rare Tumors; 2010;2(3):e54

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosa-associated lymphoid tissue lymphoma and concurrent adenocarcinoma of the prostate.
  • Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the prostate is a rare disease that characteristically follows an indolent course.
  • It is believed that infection or chronic inflammation may be triggers for malignant transformation in the prostate, but it is of unknown etiology.
  • Reports of MALT lymphomas of the prostate with other concurrent primary prostate cancers are even more limited.
  • We present the unique case of a 67-year-old male with concurrent adenocarcinoma of the prostate and primary MALT lymphoma of the prostate.
  • The patient was treated with standard therapy for prostate adenocarcinoma, which would also treat a primary MALT lymphoma.
  • This case confirms that MALT lymphoma can arise concurrently with adenocarcinoma of the prostate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139969.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994529
  • [Keywords] NOTNLM ; MALT / prostate cancer / prostate lymphoma
  •  go-up   go-down


55. Gawkowska-Suwinska M, Fijałkowski M, Białas B, Szlag M, Kellas-Ślęczka S, Nowicka E, Behrendt K, Plewicki G, Smolska-Ciszewska B, Giglok M, Zajusz A, Owczarek G: Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy. J Contemp Brachytherapy; 2009 Dec;1(4):211-215
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy.
  • PURPOSE: The aim of the study was to analyze early effects and toxicity of salvage high dose rate brachytherapy for local recurrences of adenocarcinoma of the prostate after external beam radiotherapy (EBRT).
  • MATERIAL AND METHODS: In MCS Memorial Institute of Oncology in Gliwice a research programme on salvage HDR brachytherapy for local recurrences of prostate cancer treated previously with EBRT has been ongoing since February 2008.
  • CONCLUSIONS: Salvage brachytherapy for localized prostate cancer (3 × 10 Gy every 14 days) seems to be a safe and well tolerated procedure.
  • A significant decline in prostate-specific antigen (PSA) level is seen in patients with hormone-responsive cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28050174.001).
  • [ISSN] 1689-832X
  • [Journal-full-title] Journal of contemporary brachytherapy
  • [ISO-abbreviation] J Contemp Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; prostate cancer / radiotherapy / recurrences / salvage brachytherapy
  •  go-up   go-down


56. Elias PH: Screening for adenocarcinoma of the prostate. Mayo Clin Proc; 2006 Jan;81(1):132; author reply 132-3
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for adenocarcinoma of the prostate.
  • [MeSH-major] Adenocarcinoma / epidemiology. Mass Screening. Prostatic Neoplasms / epidemiology
  • [MeSH-minor] Humans. Incidence. Male. Middle Aged. Prostate-Specific Antigen / blood. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Mayo Clin Proc. 2005 Jul;80(7):899-907 [16007895.001]
  • (PMID = 16438491.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


57. Lath CO, Khanna PC, Gadewar S, Patkar DP: Intracranial metastasis from prostatic adenocarcinoma simulating a meningioma. Australas Radiol; 2005 Dec;49(6):497-500
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial metastasis from prostatic adenocarcinoma simulating a meningioma.
  • We report an unusual case of extra-axial metastatic adenocarcinoma of the prostate that closely simulated a frontal, parasagittal, dural-based meningioma.
  • Such tumours, which satisfy several criteria for a diagnosis of meningioma, but which have proved instead to be metastatic adenocarcinoma of the prostate, form the focus of our report.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Prostatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Meningioma / radiography. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351616.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


58. Adley BP, Maxwell K, Dalton DP, Yang XJ: Urothelial-type adenocarcinoma of the prostate mimicking metastatic colorectal adenocarcinoma. Int Braz J Urol; 2006 Nov-Dec;32(6):681-7; discussion 687-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urothelial-type adenocarcinoma of the prostate mimicking metastatic colorectal adenocarcinoma.
  • Adenocarcinoma arising in urinary bladder or prostatic urethra is uncommon.
  • Here we report the fifth case of a primary urothelial-type adenocarcinoma arising in the prostate which showed enteric differentiation.
  • The patient was a 55 year-old male whose prostatic needle core biopsy showed a high grade adenocarcinoma which was initially thought to be metastatic colon cancer.
  • Subsequent prostatectomy revealed a high grade adenocarcinoma which was positive for cytokeratins 7 and 20, carcinoembryonic antigen, CDX2, and high molecular weight cytokeratin, and negative for prostate specific antigen, prostate specific acid phosphatase and AMACR.
  • A diagnosis of urothelial-type adenocarcinoma of the prostate was rendered.
  • We review the literature regarding this entity, and discuss the differential diagnosis, emphasizing utility of immunohistochemistry in making the diagnosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Necrosis. Prostatectomy. Urothelium

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17201946.001).
  • [ISSN] 1677-5538
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


59. Chadha MK, Fakih MG, Tian L, Mashtare T, Nesline M, Davis W, Silliman C, Trump DL: Effect of 25 hydroxy vitamin D status on serological response to influenza vaccine in cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of 25 hydroxy vitamin D status on serological response to influenza vaccine in cancer patients.
  • We conducted a prospective influenza vaccination study to determine the influence of vitamin D status on serological response to flu vaccine in cancer patients.
  • METHODS: Cancer patients at Roswell Park Cancer Institute were offered trivalent (H1N1, H3N2, B/Malaysia) Flu vaccine (Fluzone, 2006-7) and sera collected for hemagglutination inhibition (HI) assay titers.
  • Logistic regression model was used using other covariates such as age, gender, cancer type, and chemotherapy (CT) as controls.
  • RESULTS: 85 patients with colorectal, 35 with prostate, 1 with anal and 1 with gastric adenocarcinoma participated in the study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961109.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Lucan M, Vasiliu V, Iacob G, Lucan V: Atypical ductal adenocarcinoma of the prostate with endometrioid immunohistological features. Chirurgia (Bucur); 2009 May-Jun;104(3):355-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical ductal adenocarcinoma of the prostate with endometrioid immunohistological features.
  • We present the case of a 52-year-old Caucasian male, admitted to our institution for a verumontanum adenocarcinoma, partially resected endoscopically, a month earlier at another urological clinic.
  • The prior pathological examination wasn't able to give diagnosis.
  • The extensive assessment by clinical workup, ultrasound, flexible cystoscopy, CT scan, and MRI revealed a prostatic tumor extending from the verumontanum to the left lobe and seminal vesicle.
  • The pathological examination revealed a ductal like adenocarcinoma, positive on immunohistochemistry for pan cytokeratin (AE1/AE3), CD10, endomysial antibody EMA and progesterone receptors (PR) and negative for prostate specific antibody (PSA), prostatic specific acid phosphatase (PSAP) and androgen receptors (AR).
  • Ductal like adenocarcinoma of the prostate with endometrioid immunohistological features in the absence of prostate markers is an unusual condition.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Ductal / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Keratins / analysis. Male. Middle Aged. Mucin-1 / analysis. Neprilysin / analysis. Prostatectomy. Receptors, Progesterone / analysis. Treatment Outcome


61. Veshapidze N, Alibegashvili M, Gabunia N, Ramishvili L, Kotrikadze N: Erythrocyte membrane permeability in the men with metastatic adenocarcinoma of the prostate. Georgian Med News; 2009 Jan;(166):9-12
Hazardous Substances Data Bank. SODIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythrocyte membrane permeability in the men with metastatic adenocarcinoma of the prostate.
  • The aim of our study was to investigate the alterations of the erythrocyte membrane permeability in the men with metastatic adenocarcinoma of the prostate before and six months after castration.
  • For experimental research were used the erythrocytes of 15 men with metastatic prostate cancer (Pca) (before and after 6 months from castration) and of the 15 practically healthy men (control group).
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Membrane Permeability / physiology. Erythrocyte Membrane / metabolism. Prostatic Neoplasms / metabolism. Sodium-Potassium-Exchanging ATPase / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19202209.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 9NEZ333N27 / Sodium; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase; RWP5GA015D / Potassium
  •  go-up   go-down


62. Westphalen AC, Coakley FV, Kurhanewicz J, Reed G, Wang ZJ, Simko JP: Mucinous adenocarcinoma of the prostate: MRI and MR spectroscopy features. AJR Am J Roentgenol; 2009 Sep;193(3):W238-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma of the prostate: MRI and MR spectroscopy features.
  • OBJECTIVE: The purpose of this study was to investigate the MRI and MR spectroscopy features of mucinous adenocarcinoma of the prostate.
  • CONCLUSION: MRI and MR spectroscopy do not appear to provide the ability to reliably detect the lakes of extracellular mucin seen in mucinous adenocarcinoma of the prostate.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Magn Reson Med. 2000 Jan;43(1):17-22 [10642727.001]
  • [Cites] J Endourol. 2008 Apr;22(4):789-94 [18366322.001]
  • [Cites] AJR Am J Roentgenol. 2008 Mar;190(3):656-65 [18287436.001]
  • [Cites] Urology. 2006 Oct;68(4):825-30 [17070361.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] Eur Radiol. 2000;10(6):885-91 [10879695.001]
  • [Cites] Magn Reson Med. 2001 Dec;46(6):1079-87 [11746572.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 2):S69-75; discussion S75-6 [14610414.001]
  • [Cites] Am J Surg Pathol. 1985 Apr;9(4):299-308 [2409826.001]
  • [Cites] J Magn Reson Imaging. 1992 Sep-Oct;2(5):597-600 [1327313.001]
  • [Cites] J Magn Reson Imaging. 1997 Jul-Aug;7(4):745-57 [9243397.001]
  • [Cites] Urology. 1999 Jul;54(1):141-4 [10414741.001]
  • [Cites] Radiology. 2004 Dec;233(3):701-8 [15564406.001]
  • [Cites] Diagn Cytopathol. 2005 Aug;33(2):126-37 [16007671.001]
  • (PMID = 19696265.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA059897; United States / NIBIB NIH HHS / EB / 1 T32 EB001631-01A1; United States / NIBIB NIH HHS / EB / T32 EB001631; United States / NCI NIH HHS / CA / CA059897-16; United States / NCI NIH HHS / CA / R01 CA059897-16
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS165996; NLM/ PMC2801739
  •  go-up   go-down


63. Dohan A, Bart S, Renard-Penna R, Comperat E, Thibault F, Doerfler A, Richard F: [Ductal adenocarcinoma, four years follow-up]. Prog Urol; 2008 Dec;18(13):1093-6
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ductal adenocarcinoma, four years follow-up].
  • [Transliterated title] Adénocarcinome ductal de la prostate, quatre ans de suivi.
  • Ductal adenocarcinoma of the prostate (DAP) is an unusual form of prostatic cancer rising in the light of the acini and prostatic ducts with preservation of their architecture.
  • We report the case of a 78-year-old patient presenting a pure ductal adenocarcinoma of the prostate locally advanced, with a four years' follow-up.
  • [MeSH-major] Adenocarcinoma. Prostatic Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041818.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 7
  •  go-up   go-down


64. Samaratunga H, Delahunt B: Ductal adenocarcinoma of the prostate: current opinion and controversies. Anal Quant Cytol Histol; 2008 Aug;30(4):237-46
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal adenocarcinoma of the prostate: current opinion and controversies.
  • OBJECTIVE: To evaluate the morphologic spectrum and clinical significance of ductal adenocarcinoma of the prostate (DAP).
  • STUDY DESIGN: We reviewed diagnostic criteria, including the value of immunohistochemistry, and outlined the prognostic implications of a diagnosis of DAP.
  • DAP is found in both the periurethral region and peripheral zone of the prostate and is considered high grade in the modified Gleason grading system.
  • Immunostaining for prostatic-specific antigen and prostate-specific acid phosphatase is present in these tumors, a high percentage of which overexpress alpha-methylacyl-coenzyme A racemase.
  • CONCLUSION: DAP are neoplasms of prostatic origin, and the terms endometrioid or endometrial adenocarcinoma are best avoided.
  • DAP are aggressive tumors with a shortened average time to progression compared with acinar adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773743.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


65. Lawton CA, Winter K, Grignon D, Pilepich MV: Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol; 2005 Feb 1;23(4):800-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.
  • PURPOSE: To update the effect of immediate androgen suppression in conjunction with standard external-beam irradiation versus radiation alone on a group of histologically lymph node-positive patients with adenocarcinoma of the prostate.
  • MATERIALS AND METHODS: A national prospective randomized trial (Radiation Therapy Oncology Group 85-31) of standard external-beam irradiation plus immediate androgen suppression versus external-beam irradiation alone was initiated in 1985 for patients with locally advanced adenocarcinoma of the prostate.
  • RESULTS: With a median follow-up of 6.5 years for all patients and 9.5 years for living patients, estimated progression-free survival with prostate-specific antigen (PSA) level less than 1.5 ng/mL at 5 and 9 years was 54% and 33%, respectively, for patients who received immediate LHRH agonist versus 10% [corrected] and 4% for patients who received radiation alone with hormonal manipulation instituted at time of relapse (P < .0001).
  • CONCLUSION: Pending the results of randomized trials, patients with adenocarcinoma of the prostate who have pathologically involved pelvic lymph nodes (pathologic node-positive or clinical stage D1) should be considered for external-beam irradiation plus immediate hormonal manipulation rather than radiation alone with hormone manipulation at the time of relapse.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Goserelin / therapeutic use. Prostatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GOSERELIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2005 Dec 1;23(34):8921
  • (PMID = 15681524.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0F65R8P09N / Goserelin
  •  go-up   go-down


66. Stevenson MM, Mostertz W, Acharya C, Walters K, Barry W, Tuchman S, Ready N, Onaitis M, Crawford J, Potti A: Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):11001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.
  • : 11001 Background: Cancer cells possess traits reminiscent of those ascribed to normal stem cells.
  • It is unclear whether these phenotypic similarities between normal/embryonic stem cells and mature tumor cells, specific to lung cancer, are a result of underlying biologic processes, such as specific molecular pathways and regulatory networks.
  • METHODS: Using a large cohort of lung cancer cell lines with associated gene expression data, genes associated with an embryonic stem cell identity were used to develop a 'signature' representative of embryonic stemness (ES) activity specific to lung adenocarcinoma.
  • The ES signature was applied to three independent early (stage I - IIIa) lung adenocarcinoma data sets (N = 634) with clinically annotated gene expression data.
  • RESULTS: Using Bayesian regression analysis, a 100 gene signature representative of ES activity in lung adenocarcinoma was developed and validated in a leave-one-out-analysis.
  • GSEA identified gene sets significantly represented in the ES signature: signature of neoplastic transformation, signature of undifferentiated cancer, BRCA pathway, and fibroblast serum response pathway, all associated with cancer invasiveness.
  • The ES signature was not prognostic in prostate, ovarian, or breast adenocarcinomas.
  • Lung tumors (N=634) and adenocarcinoma cell lines (N=31) with ES were more resistant to cisplatin (p<0.0001 and p=0.0063, respectively).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964049.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Kasibhatla M, Peterson B, Anscher MS: What is the best postoperative treatment for patients with pT3bN0M0 adenocarcinoma of the prostate? Prostate Cancer Prostatic Dis; 2005;8(2):167-73
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is the best postoperative treatment for patients with pT3bN0M0 adenocarcinoma of the prostate?
  • The purpose of this paper to identify the optimal therapy after radical prostatectomy (RP) for patients with adenocarcinoma of the prostate invading the seminal vesicles (pT3bN0M0 or SVI).
  • A PubMed search using the keywords 'prostate', 'seminal vesicle', 'prostatectomy', 'radiotherapy', 'androgen blockade' was performed to identify literature regarding rates of disease failure in patients with SVI who are observed or treated with androgen blockade (AB), radiotherapy (RT) or RT + AB after RP.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Androgen Antagonists / therapeutic use. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15711603.001).
  • [ISSN] 1365-7852
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen Antagonists
  • [Number-of-references] 33
  •  go-up   go-down


68. Samaratunga H, Duffy D, Yaxley J, Delahunt B: Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension. Hum Pathol; 2010 Feb;41(2):281-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension.
  • Ductal adenocarcinoma of the prostate is an aggressive malignancy, often presenting at an advanced stage.
  • From 268 consecutive radical prostatectomies undertaken as a curative procedure for clinical localized prostate cancer, we identified 34 cases (12.7%) with ductal adenocarcinoma of the prostate comprising 5% to 100% of the total tumor volume.
  • For cases with a ductal adenocarcinoma of the prostate component, the mean age at diagnosis of 60 years (range 49-69 years), mean serum prostate-specific antigen of 8.4 ng/mL (range, 0.8-21 ng/mL) and positive surgical margin rate of 17.6% did not differ significantly from that of the pure adenocarcinoma group.
  • All 34 patients with ductal adenocarcinoma of the prostate had peripheral zone involvement while 16 (46%) also had transition zone involvement.
  • Twenty-five (73%) cases with ductal adenocarcinoma of the prostate had extraprostatic extension (pT3), which compared to 32.9% with acinar adenocarcinoma.
  • The presence of ductal adenocarcinoma of the prostate (P < .0001), high tumor volume (P = .001) and Gleason score >7 (P = .04) significantly predicted pT3 staging category, and the presence of ductal adenocarcinoma of the prostate remained a significant predictor for pT3, after adjusting for tumor volume and Gleason score >7.
  • The proportion of ductal adenocarcinoma of the prostate did not significantly modify the strength of the observed association with pathological stage.
  • In view of the significant association with extraprostatic extension we would recommend that in both core biopsies and radical prostatectomy specimens any proportion of ductal adenocarcinoma of the prostate should be reported.
  • [MeSH-major] Carcinoma, Ductal / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Odds Ratio. Predictive Value of Tests. Prostate-Specific Antigen / blood. Prostatectomy. Regression (Psychology)

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Hum Pathol. 2011 Apr;42(4):605-6; author reply 606-7 [21237485.001]
  • (PMID = 20004936.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


69. Tamas EF, Epstein JI: Prognostic significance of paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate. Am J Surg Pathol; 2006 Aug;30(8):980-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate.
  • The prognostic significance of Paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate has not yet been established.
  • We studied 36 cases of adenocarcinoma of the prostate showing Paneth cell-like neuroendocrine differentiation, including needle biopsy specimens (n = 27), radical prostatectomies (n = 8), and transurethral resection specimens (n = 1).
  • In 4 cases, seminal vesicles were positive for cancer.
  • The actuarial prostate specific antigen progression-free risk at 5 years and 7 years was 92% and 80%, respectively.
  • Only 2 patients progressed after radical prostatectomy and they both had Gleason score 7 cancer with extraprostatic extension and seminal vesicle invasion.
  • In cases with Paneth cell-like NECs, only the conventional adenocarcinoma component should be assigned a Gleason score.
  • [MeSH-major] Adenocarcinoma / pathology. Paneth Cells / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861969.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


70. Lawton CA, DeSilvio M, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky T, Sandler H: Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). Int J Radiat Oncol Biol Phys; 2007 Jan 1;67(1):39-47
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05).
  • PURPOSE: To evaluate the effectiveness of transrectal ultrasound-guided permanent radioactive (125)I implantation of the prostate for organ-confined adenocarcinoma of the prostate compared with historical data of prostatectomy and external beam radiotherapy within a cooperative group setting.
  • METHODS AND MATERIALS: Patients accrued to this study had histologically confirmed, locally confined, adenocarcinoma of the prostate with clinical Stage T1b, T1c, or T2a, no nodal or metastatic disease, prostate-specific antigen level of < or =10 ng/mL, and Gleason score of < or =6.
  • All patients underwent transrectal ultrasound-guided radioactive (125)I permanent seed implantation into the prostate.
  • The prescribed dose was 145 Gy to the prostate planning target volume.
  • At last follow-up, no patient had died of prostate cancer or related toxicities.
  • CONCLUSION: The results of this clinical protocol (a multi-institutional trial of brachytherapy for localized adenocarcinoma of the prostate) have demonstrated that this type of trial can be successfully completed through the Radiation Therapy Oncology Group.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Prostatic Neoplasms / radiotherapy. Ultrasonography, Interventional / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Disease-Free Survival. Humans. Iodine Radioisotopes / therapeutic use. Male. Middle Aged. Neoplasm Staging. Prognosis. Prostate-Specific Antigen / blood. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084551.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


71. Veshapidze N, Chigogidze T, Managadze L, Gabunia N, Kotrikadze N: Dynamics of the structural and electrical characteristics of erythrocytes in men with metastatic adenocarcinoma of the prostate before and after plastic orchiectomy. Georgian Med News; 2007 Dec;(153):11-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamics of the structural and electrical characteristics of erythrocytes in men with metastatic adenocarcinoma of the prostate before and after plastic orchiectomy.
  • The changes of electrophoretic mobility of erythrocytes in the practically healthy men and in men with metastatic prostate cancer before and after castration were studied.
  • Investigation revealed, that the level of electrophoretic mobility of erythrocytes was decreased in the blood of metastatic prostate cancer patients (before castration), as compared with control group and with post operational period data.
  • It was found, that during the malignant adenocarcinoma of prostate (before and after surgery) pathological changes in organism effect erythrocytes superficial membranes and alter their electrical and structural parameters.
  • Probably, that is one of the reasons of considerable decrease of erythrocytes electrophoretic mobility in patients with metastatic prostate adenocarcinoma (before castration).
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Erythrocytes / metabolism. Erythrocytes / ultrastructure. Orchiectomy / methods. Postoperative Care. Preoperative Care. Prostatic Neoplasms / secondary. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18250488.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


72. Hansel DE, Nakayama M, Luo J, Abukhdeir AM, Park BH, Bieberich CJ, Hicks JL, Eisenberger M, Nelson WG, Mostwin JL, De Marzo AM: Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate; 2009 May 1;69(6):603-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.
  • BACKGROUND: Small cell carcinoma of the prostate is an uncommon neoplasm, the origin of which has been controversial.
  • To address this, we performed transcriptome profiling and TP53 sequencing of concurrent small cell and prostatic adenocarcinoma to determine the relationship between these entities.
  • METHODS: We identified an unusual case of primary prostate cancer that contained adjacent acinar adenocarcinoma (Gleason score 4 + 3 = 7) and small cell carcinoma.
  • RESULTS: Transcriptome profiling of the carcinoma components identified 99 genes with a greater than 10-fold differential expression between prostatic adenocarcinoma and small cell carcinoma, many of which have not been previously reported in prostate cancer.
  • CONCLUSIONS: This is the first report of a primary small cell carcinoma of the prostate subjected to extensive molecular analysis and the first to show a clonal relation between two morphologically distinct prostate cancer types.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6 [14711987.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):217-27 [14695335.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Aug;5(8):614-25 [15366705.001]
  • [Cites] Cancer. 1987 May 15;59(10):1803-9 [3030528.001]
  • [Cites] Cell. 1992 Jul 24;70(2):293-301 [1638632.001]
  • [Cites] Gastroenterology. 1994 Aug;107(2):420-8 [8039618.001]
  • [Cites] Cancer Res. 1997 Feb 1;57(3):524-31 [9012485.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 15;91(18):1574-80 [10491435.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9209-16 [15604294.001]
  • [Cites] Eur Urol. 2005 Feb;47(2):147-55 [15661408.001]
  • [Cites] FASEB J. 2005 Feb;19(2):243-5 [15548588.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):393-406 [16286247.001]
  • [Cites] J Neurosci. 2005 Nov 16;25(46):10773-85 [16291951.001]
  • [Cites] Am J Surg Pathol. 2006 Jun;30(6):684-93 [16723845.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10683-90 [17108105.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):41-51 [17173048.001]
  • [Cites] Neoplasia. 2007 Feb;9(2):166-80 [17356713.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8460-7 [17875684.001]
  • [Cites] Urol Int. 1999;62(3):133-8 [10529661.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21525-31 [10781613.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4683-8 [11406537.001]
  • [Cites] Blood Cells Mol Dis. 2001 Sep-Oct;27(5):825-9 [11783945.001]
  • [Cites] Prostate. 2002 May 15;51(3):189-200 [11967953.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4499-506 [12154061.001]
  • [Cites] Prostate. 2003 Apr 1;55(1):55-64 [12640661.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2790-9 [15254046.001]
  • (PMID = 19125417.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA058236-10; United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / P50 CA058236; United States / NCI NIH HHS / CA / P50 CA058236-10
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS285484; NLM/ PMC3170854
  •  go-up   go-down


73. Routh JC, Leibovich BC: Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. Mayo Clin Proc; 2005 Jul;80(7):899-907
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease.
  • Prostate cancer is a leading cause of mortality and morbidity worldwide.
  • Despite years of study and effort, certain key questions remain unanswered, including how prostate cancer is best detected and diagnosed, how it is best treated, and how best to minimize the complications of treatment.
  • The aim of this article is to briefly address these topics to shed light on the current best practices in prostate cancer screening, diagnosis, and surgical treatment of localized disease.
  • We examine current trends in prostate cancer epidemiology and screening, including genetic and dietary risk factors and the newer prostate-specific antigen-derived screening modalities.
  • Methods of diagnosis, including an overview of prostate biopsy technique and indications, and a brief review of relevant pathologic findings are provided.
  • An in-depth analysis of traditional prostate cancer surgical management highlights the relevant advantages and disadvantages of radical retropubic and perineal prostatectomy.
  • In all, this article aims to give the reader a broad overview of the basic elements of prostate cancer diagnosis and surgical treatment in the modem era.
  • [MeSH-major] Adenocarcinoma. Prostatic Neoplasms
  • [MeSH-minor] Humans. Incidence. Male. Mass Screening. Neoplasm Staging. Prevalence. Prognosis. Prostate-Specific Antigen / blood. Prostatectomy / adverse effects. Prostatectomy / methods. Risk Factors. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Mayo Clin Proc. 2006 Jan;81(1):132; author reply 132-3 [16438491.001]
  • (PMID = 16007895.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 115
  •  go-up   go-down


74. Bettendorf O, Schmidt H, Staebler A, Grobholz R, Heinecke A, Boecker W, Hertle L, Semjonow A: Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate. Genes Chromosomes Cancer; 2008 Jul;47(7):565-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate.
  • Recent studies have shown that intraductal prostate carcinoma (IDC-P) should be considered as a separate lesion distinct from prostatic intraepithelial neoplasia (PIN).
  • The purpose of the present study was to analyze the genetic relationship between benign prostatic tissue, PIN, invasive cancer, IDC-P, and extracapsular tumor tissue to get further information about the role of IDC-P in the development of prostate cancer.
  • LOH of both TP53 and RB1 were frequently found in IDC-P (52%), followed by extracapsular tumor tissue (44%), invasive cancer (24%), PIN (19%), and benign prostatic tissue (17%).
  • Increased immunohistochemical expression was found in invasive cancer for TP53, RB1, and for PTEN.
  • IDC-P represents a separate prostatic lesion and should be graded as a poorly differentiated carcinoma.
  • [MeSH-major] Chromosomal Instability. Loss of Heterozygosity. PTEN Phosphohydrolase / metabolism. Prostatic Neoplasms / genetics. Prostatic Neoplasms / metabolism. Retinoblastoma Protein / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Prostatic Intraepithelial Neoplasia / genetics. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Intraepithelial Neoplasia / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18383208.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Retinoblastoma Protein; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


75. Osunkoya AO, Hansel DE, Sun X, Netto GJ, Epstein JI: Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am J Surg Pathol; 2008 Mar;32(3):461-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases.
  • Aberrant diffuse expression of p63 in prostate carcinoma cells is a rare and poorly understood phenomenon.
  • We studied 19 cases of prostate cancer with aberrant diffuse expression of p63 on needle biopsy and reviewed the subsequent radical prostatectomies in 6 cases.
  • In 19/21 cases, 100% of the cancer nuclei stained intensely for p63, with 70% staining in the remaining 2 cases.
  • In all 8 radical prostatectomies p63 positive cancer was present, with in 2/8 cases both p63 positive cancer and usual p63 negative acinar prostate cancer.
  • The presence of p63 positive atypical glands with an infiltrative pattern and perineural invasion on radical prostatectomy confirmed the needle biopsy diagnosis of carcinoma.
  • Rarely, prostate cancer can aberrantly express diffuse p63 staining in a nonbasal cell distribution leading to the erroneous diagnosis of atrophy or atypical basal cell proliferation.
  • The diagnosis of prostate cancer is based on the morphology and confirmed by the absence of high molecular weight cytokeratin staining and positivity for alpha-methylacyl-CoA racemase in the atypical glands.
  • Pathologists need to be aware of this rare and unusual phenomenon, which is a potential pitfall in prostate cancer diagnosis.
  • [MeSH-major] Adenocarcinoma / chemistry. Biopsy, Needle. Membrane Proteins / analysis. Prostatectomy. Prostatic Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300803.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


76. Helpap B: The significance of the P504S expression pattern of high-grade prostatic intraepithelial neoplasia (HGPIN) with and without adenocarcinoma of the prostate in biopsy and radical prostatectomy specimens. Virchows Arch; 2006 Apr;448(4):480-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of the P504S expression pattern of high-grade prostatic intraepithelial neoplasia (HGPIN) with and without adenocarcinoma of the prostate in biopsy and radical prostatectomy specimens.
  • Diagnosis of prostatic adenocarcinoma is usually not difficult in biopsy specimens.
  • Recently, P504S has been tested as a new marker for prostatic carcinoma.
  • When over-expressed in atypical glands without basal cells, it establishes the diagnosis of prostatic carcinoma.
  • We analysed the staining intensity of P504S in 208 biopsy specimens from prostates (1) with adenocarcinoma (n=132), (2) with high-grade prostatic intraepithelial neoplasia (HGPIN) with adenocarcinoma (n=36), (3) with HGPIN alone (n=40) and in radical prostatectomy specimens with HGPIN adjacent to (n=54) or distant from adenocarcinoma (n=64).
  • P504S expression was negative to weakly positive in biopsy specimens showing HGPIN without carcinoma and weakly positive in radical prostatectomy specimens revealing HGPIN distant from adenocarcinoma.
  • In biopsy specimens with a combination of HGPIN and adenocarcinoma and in radical prostatectomy specimens with HGPIN adjacent to adenocarcinoma, P504S was strongly expressed.
  • The same findings were made in radical prostatectomy specimens containing adenocarcinoma and HGPIN adjacent to or distant from adenocarcinoma and in preoperative biopsies revealing adenocarcinoma and HGPIN.
  • These results suggest that moderate to strong P504S expression in HGPIN of biopsy specimens is indicative of an associated adenocarcinoma and may be helpful in the choice of therapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Neoplasms, Multiple Primary / metabolism. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Neoplasms / metabolism. Racemases and Epimerases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):772-8 [12766580.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1588-96 [12459625.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1435-41 [16224209.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):629-33 [15105651.001]
  • [Cites] Hum Pathol. 2003 Aug;34(8):792-6 [14506641.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1169-74 [12218573.001]
  • [Cites] Pathol Res Pract. 1999;195(12):795-9 [10631713.001]
  • [Cites] Histopathology. 2004 Sep;45(3):218-25 [15330799.001]
  • [Cites] Virchows Arch. 1998 Nov;433(5):397-405 [9849853.001]
  • [Cites] Histopathology. 2004 Apr;44(4):403-4 [15049912.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2220-6 [11956072.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):1008-13 [15297968.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):926-31 [12131161.001]
  • [Cites] J Pathol. 2001 Mar;193(3):350-3 [11241415.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1128-33 [12883245.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1662-70 [11926890.001]
  • [Cites] Verh Dtsch Ges Pathol. 2004;88:152-7 [16892546.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):239-43 [15043314.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] Histopathology. 2005 Jul;47(1):1-16 [15982318.001]
  • (PMID = 16506014.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


77. Nakanishi S, Hatayama T: [Adenocarcinoma of the prostate associated with anti Jo-1 antibody positive polymyositis]. Hinyokika Kiyo; 2006 Apr;52(4):289-91
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenocarcinoma of the prostate associated with anti Jo-1 antibody positive polymyositis].
  • A 76-year-old male was hospitalized with elevation of prostate specific antigen.
  • Adenocarcinoma was classified as Gleason score 8 by needle biopsy of the prostate and the stage of the prostate carcinoma was cT3aN1M0.
  • [MeSH-major] Adenocarcinoma / complications. Antibodies, Antinuclear / immunology. Polymyositis / immunology. Prostatic Neoplasms / complications

  • Genetic Alliance. consumer health - Polymyositis.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16686358.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Antinuclear; 0 / Jo-1 antibody; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


78. Hudson E, Kynaston H, Varma M, Carter A, Staffurth J, Barber J, Mason MD, Lester JF: Radiotherapy after radical prostatectomy for adenocarcinoma of the prostate: a UK institutional experience and review of published studies. Clin Oncol (R Coll Radiol); 2008 Jun;20(5):353-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy after radical prostatectomy for adenocarcinoma of the prostate: a UK institutional experience and review of published studies.
  • AIMS: The role of radiotherapy to the prostate bed after radical prostatectomy is the subject of much debate.
  • We carried out a retrospective analysis of all patients treated with either adjuvant radiotherapy (ART) or salvage radiotherapy (SRT) in a single UK cancer centre and compared outcomes with published studies.
  • SRT was carried out in patients with a detectable or rising prostate-specific antigen (PSA) postoperatively.
  • A PSA at diagnosis<10 ng/ml, positive surgical margins, absence of seminal vesicle involvement and neoadjuvant hormones were all associated with a trend towards improved BPFS.
  • CONCLUSIONS: The results from this series are in line with published studies, and support the evidence that prostate bed radiotherapy may affect biochemical control in a proportion of patients at risk of relapse.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Prostatectomy. Prostatic Neoplasms / radiotherapy. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18407476.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


79. Rabinovsky R, Uhr JW, Vitetta ES, Yefenof E: Cancer dormancy: lessons from a B cell lymphoma and adenocarcinoma of the prostate. Adv Cancer Res; 2007;97:189-202
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer dormancy: lessons from a B cell lymphoma and adenocarcinoma of the prostate.
  • Cancer dormancy delineates a situation in which residual tumor cells persist in a patient with no apparent clinical symptoms.
  • Although the precise mechanisms underlying cancer dormancy have not been explained, experimental models have provided some insights into the factors that might be involved in the induction and maintenance of a tumor dormant state.
  • In contrast, antibodies against HER-2expressed on prostate adenocarcinoma (PAC) cells were not growth inhibitory.
  • Hence, certain aspects of signaling receptors expressed on cancer can be manipulated by antibodies to induce and maintain a tumor dormant state.
  • [MeSH-major] Adenocarcinoma / pathology. Immunologic Surveillance. Lymphoma, B-Cell / pathology. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. RICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419946.001).
  • [ISSN] 0065-230X
  • [Journal-full-title] Advances in cancer research
  • [ISO-abbreviation] Adv. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Immunotoxins; 0 / Receptors, Antigen, B-Cell; 9009-86-3 / Ricin; EC 2.7.10.1 / Receptor, ErbB-2
  • [Number-of-references] 69
  •  go-up   go-down


80. Resnick MJ, Wein AJ: Transitional cell carcinoma of the fossa navicularis in a man with preexisting adenocarcinoma of the prostate. Urol Int; 2006;76(2):186-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the fossa navicularis in a man with preexisting adenocarcinoma of the prostate.
  • In this report we present a patient with a history of prostatic adenocarcinoma who was found to have a low-grade/low-stage transitional cell carcinoma of the fossa navicularis.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Transitional Cell / diagnosis. Neoplasms, Multiple Primary. Prostatic Neoplasms. Urethral Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16493225.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


81. Dziuba K: A case study: ductal adenocarcinoma of the prostate. Urol Nurs; 2009 Nov-Dec;29(6):422-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case study: ductal adenocarcinoma of the prostate.
  • Ductal carcinoma of the prostate (generally arising from prostatic ducts) is a rare but often aggressive variant of prostate cancer.
  • In ductal prostate cancer, digital rectal examination and prostate specific antigen level can be unreliable because both may be normal.
  • This article presents a case study following the diagnosis and successful treatment of a patient through two clinics, and stresses how nurses can ensure continuity of care from one facility to another.
  • [MeSH-major] Carcinoma, Ductal / therapy. Prostatic Neoplasms / therapy
  • [MeSH-minor] Aged, 80 and over. Brachytherapy. Continuity of Patient Care. Hematuria / etiology. Humans. Male. Nurse Practitioners. Transurethral Resection of Prostate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20088233.001).
  • [ISSN] 1053-816X
  • [Journal-full-title] Urologic nursing
  • [ISO-abbreviation] Urol Nurs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Hébert-Blouin MN, Amrami KK, Myers RP, Hanna AS, Spinner RJ: Adenocarcinoma of the prostate involving the lumbosacral plexus: MRI evidence to support direct perineural spread. Acta Neurochir (Wien); 2010 Sep;152(9):1567-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the prostate involving the lumbosacral plexus: MRI evidence to support direct perineural spread.
  • BACKGROUND: Prostate adenocarcinoma, which may recur despite aggressive treatment, has the potential to spread to the lumbosacral plexus.
  • METHODS: The clinical data and imaging studies (magnetic resonance imaging, MRI, and positron emission tomography/computed tomography, PET/CT) of patients evaluated at our institution between 2004 and 2009 for lumbosacral plexopathy due to intraneural prostate carcinoma were retrospectively reviewed.
  • RESULTS: Four patients presenting with painful lumbosacral plexopathy were found to have intraneural lumbosacral prostate adenocarcinoma.
  • Two patients had involvement of the lumbosacral plexus ipsilateral to the lobe of the prostate most involved with adenocarcinoma at prostatectomy.
  • High-resolution MRI and PET/CT studies revealed similar findings: abnormal soft tissue signal was followed from the prostate (n = 1) or prostatic bed (n = 3) area along the expected course of the pelvic plexus to the level of the sciatic notch, where it involved the sacral spinal nerves and sciatic nerve.
  • CONCLUSIONS: The potential for prostate adenocarcinoma to spread to the lumbosacral plexus has, to our knowledge, not been readily appreciated.
  • This study, with the use of high-resolution MRI and PET/CT studies, supports the direct perineural spread of prostate adenocarcinoma via the pelvic plexus to the lumbosacral plexus.
  • This mechanism could also explain cases of leptomeningeal and/or dural-based prostate metastases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Lumbosacral Plexus / pathology. Peripheral Nerves / pathology. Peripheral Nervous System Neoplasms / diagnosis. Peripheral Nervous System Neoplasms / pathology. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness / diagnosis. Neoplasm Invasiveness / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20473531.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


83. White WM, Sadetsky N, Waters WB, Carroll PR, Litwin MS: Quality of life in men with locally advanced adenocarcinoma of the prostate: an exploratory analysis using data from the CaPSURE database. J Urol; 2008 Dec;180(6):2409-13; discussion 2414
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life in men with locally advanced adenocarcinoma of the prostate: an exploratory analysis using data from the CaPSURE database.
  • PURPOSE: We present longitudinal quality of life outcomes in a national observational cohort of men with locally advanced prostate adenocarcinoma.
  • MATERIALS AND METHODS: The CaPSURE registry was used to evaluate quality of life in men with clinical T3 or T4 prostate adenocarcinoma who underwent primary treatment and had a minimum followup of 2 years.
  • Records were reviewed for treatment, patient age, T stage, prostate specific antigen at diagnosis, body mass index, and initial and posttreatment quality of life using the SF-36 and UCLA-PCI questionnaires, which can each be scored from 0 to 100 with higher scores indicating better outcomes.
  • CONCLUSIONS: Treatment for locally advanced prostate adenocarcinoma is associated with a significant burden in patients, notably decrements in urinary and sexual function.
  • [MeSH-major] Adenocarcinoma / therapy. Prostatic Neoplasms / therapy. Quality of Life. Registries

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18930270.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Tavora F, Epstein JI: High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases. Am J Surg Pathol; 2008 Jul;32(7):1060-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
  • Most of the prostatic ductal adenocarcinomas of the prostate are characterized by cribriform and/or papillary architecture lined by columnar pseudostratified malignant epithelium.
  • We report 28 cases of ductal adenocarcinomas on needle biopsy and transurethral resection of prostate closely resembling high-grade prostatic intraepithelial neoplasia (HGPIN) composed of simple glands with flat, tufting, or micropapillary architecture.
  • Prostate specific antigen serum level at diagnosis ranged from 1.2 to 12.1 ng/mL.
  • Three patients had recent biopsies without information on treatment and 3 patients were lost to follow-up after diagnosis.
  • Fourteen cases revealed segments of dilated gland on the edge of the biopsies, suggesting a large gland component.
  • In radical prostatectomies, tumor was primarily composed of small (25%), medium (17%), or cystically dilated (58%) cancer glands, with all cases demonstrating a mixture of different gland sizes.
  • PIN-like ductal adenocarcinoma differs from HGPIN by the presence of cystically dilated glands, a greater predominance of flat architecture, and less frequently prominent nucleoli.
  • Although usual ductal adenocarcinoma is considered comparable to Gleason score 8, PIN-like ductal adenocarcinoma was accompanied by Gleason score 6 acinar carcinoma and behaved similar to Gleason score 6 acinar cancer.
  • Recognition of this entity is critical to differentiate it from both HGPIN and conventional ductal adenocarcinoma.
  • [MeSH-major] Carcinoma, Ductal / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Biomarkers, Tumor / analysis. Biopsy, Needle. Cryotherapy. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Prostatectomy. Radiotherapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18496142.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


85. Luebke AM, Schlomm T, Gunawan B, Bonkhoff H, Füzesi L, Erbersdobler A: Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach. Virchows Arch; 2005 Mar;446(3):338-41
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach.
  • Basal cell tumours of the prostatic gland are rare, and the classification is difficult.
  • In the present case report, a large, tumour-like proliferation of atypical basaloid cells was found incidentally in a prostatectomy specimen that otherwise contained a conventional acinar adenocarcinoma.
  • A high Ki-67 index was recorded within the atypical basaloid cells, by far exceeding the one counted in the conventional adenocarcinoma.
  • Comparative genomic hybridisation from microdissected tumour cells yielded losses at the short arms of chromosomes 8 and 12 in the conventional adenocarcinoma and a normal karyotype in the basal cell tumour.
  • The pathological findings favoured the diagnosis of an atypical basal cell hyperplasia.
  • [MeSH-major] Carcinoma, Acinar Cell / complications. Carcinoma, Acinar Cell / pathology. Prostatic Hyperplasia / complications. Prostatic Hyperplasia / pathology. Prostatic Neoplasms / complications. Prostatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasms, Basal Cell / genetics. Neoplasms, Basal Cell / pathology. Nucleic Acid Hybridization

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1993 Aug;117(8):799-801 [8343043.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):342-7 [7529134.001]
  • [Cites] Eur Urol. 1999;36(1):21-30 [10364651.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):668-72 [14999772.001]
  • [Cites] Histopathology. 1992 Feb;20(2):151-5 [1559669.001]
  • [Cites] Pathol Res Pract. 1990 Feb;186(1):28-36 [2179908.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):645-59 [7686348.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):231-43 [7522536.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):202-8 [11161378.001]
  • [Cites] Mod Pathol. 1997 Jun;10(6):612-29 [9195581.001]
  • [Cites] Virchows Arch. 2003 Dec;443(6):787-91 [14756145.001]
  • [Cites] Hum Pathol. 1988 Dec;19(12):1425-33 [2461340.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1523-9 [14657711.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):399-406 [11159178.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):43-51 [12107088.001]
  • [Cites] Am J Surg Pathol. 1992 Dec;16(12):1205-14 [1281386.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1225-33 [2400973.001]
  • [Cites] Hum Pathol. 1998 Dec;29(12):1447-50 [9865831.001]
  • (PMID = 15726402.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


86. Hussein K, Nanda A, Al-Sabah H, Alsaleh QA: Sweet's syndrome (acute febrile neutrophilic dermatosis) associated with adenocarcinoma of prostate and transitional cell carcinoma of urinary bladder. J Eur Acad Dermatol Venereol; 2005 Sep;19(5):597-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sweet's syndrome (acute febrile neutrophilic dermatosis) associated with adenocarcinoma of prostate and transitional cell carcinoma of urinary bladder.
  • In the present report, we describe an 82-year-old male with SS in association with adenocarcinoma of the prostate and transitional cell carcinoma of the urinary bladder.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Transitional Cell / pathology. Neoplasms, Multiple Primary / diagnosis. Prostatic Neoplasms / pathology. Sweet Syndrome / diagnosis. Urinary Bladder Neoplasms / pathology


87. Metzdorf MM, Schmidt JD: Isolated prostate cancer recurrence presenting as pelvic mass nine years after radical retropubic prostatectomy. Urology; 2007 Nov;70(5):1007.e17-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated prostate cancer recurrence presenting as pelvic mass nine years after radical retropubic prostatectomy.
  • Pelvic seeding from radical retropubic prostatectomy for adenocarcinoma of the prostate is uncommon.
  • We describe a patient who presented with a prostate-specific antigen recurrence and was found to have a solitary metastasis adjacent to his pubic bone 9 years after radical prostatectomy.
  • [MeSH-major] Adenocarcinoma / surgery. Neoplasm Seeding. Pelvic Neoplasms / diagnosis. Prostatectomy. Prostatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068468.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Wright JL, Lin DW, Dewan P, Montgomery RB: Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer. Int J Urol; 2005 Nov;12(11):1012-3
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer.
  • We report a case of TLS in a patient with metastatic adenocarcinoma of the prostate after treatment with paclitaxel chemotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents, Phytogenic / adverse effects. Paclitaxel / adverse effects. Prostatic Neoplasms / therapy. Tumor Lysis Syndrome / etiology
  • [MeSH-minor] Bone Marrow Neoplasms / drug therapy. Bone Marrow Neoplasms / secondary. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Hematuria / etiology. Humans. Hydronephrosis / etiology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Middle Aged. Prostate-Specific Antigen / blood. Renal Dialysis. Renal Insufficiency / etiology. Renal Insufficiency / therapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351664.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; EC 3.4.21.77 / Prostate-Specific Antigen; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


89. Gerst SR, Touijer AK, Guillonneau B, Al-Ahmadie H, Mehdizade A: The importance of MRI evaluation in the preoperative work-up of prostate cancer. Nat Clin Pract Urol; 2005 Nov;2(11):565-71; quiz 572
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of MRI evaluation in the preoperative work-up of prostate cancer.
  • BACKGROUND: A 59-year-old man on exogenous androgen therapy presented with a clinically palpable prostate nodule confined to one lobe on endorectal examination.
  • Serum prostate-specific antigen was 3.4 ng/ml.
  • INVESTIGATIONS: Physical examination, laboratory evaluation, endorectal MRI of the prostate, cystoscopy and biopsy.
  • DIAGNOSIS: Poorly differentiated adenocarcinoma of the prostate, with invasion of the urinary bladder.
  • [MeSH-major] Adenocarcinoma / diagnosis. Magnetic Resonance Imaging. Prostatic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16474600.001).
  • [ISSN] 1743-4270
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Kawahara T, Manabe Y, Asazuma A, Aoyama T, Hashimura T: [Hormone refractory prostate carcinoma metastasizes to the penis: a case report]. Hinyokika Kiyo; 2009 Oct;55(10):627-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hormone refractory prostate carcinoma metastasizes to the penis: a case report].
  • At 67-years-old, he was diagnosed with stage D2 prostate cancer and then, was treated with hormone therapy.
  • Several nodules were observed on the glans, and histological examination of the penile tumor biopsy showed metastatic adenocarcinoma of the prostate.
  • For the purpose of maintaining quality of life, transurethral resection of the prostate and partial penectomy were done.
  • [MeSH-major] Adenocarcinoma / pathology. Penile Neoplasms / secondary. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19938335.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists
  •  go-up   go-down


91. Gore JL, Penson DF, Litwin MS: Discussing quality-of-life issues with a patient newly diagnosed with prostate cancer. Nat Clin Pract Urol; 2006 Aug;3(8):449-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discussing quality-of-life issues with a patient newly diagnosed with prostate cancer.
  • BACKGROUND: A 66-year-old man with hypertension, hyperlipidemia, and benign prostatic hyperplasia presented for evaluation of an elevated PSA level of 6.2 ng/ml.
  • INVESTIGATIONS: Transrectal ultrasound-guided 12-core prostate needle biopsy.
  • DIAGNOSIS: Clinically localized, clinical stage T1c adenocarcinoma of the prostate.
  • [MeSH-major] Adenocarcinoma / psychology. Physician-Patient Relations. Prostatectomy / psychology. Prostatic Neoplasms / psychology. Quality of Life
  • [MeSH-minor] Aged. Biopsy. Humans. Male. Prostate-Specific Antigen / blood


92. Crijns W, Budiharto T, Defraene G, Verstraete J, Depuydt T, Haustermans K, Van den Heuvel F: IMRT-based optimization approaches for volumetric modulated single arc radiotherapy planning. Radiother Oncol; 2010 May;95(2):149-52
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study includes 11 patients with adenocarcinoma of the prostate.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Prostatic Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted / instrumentation. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Intensity-Modulated / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20171750.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


93. Chadrawar S, George M, Al-Akraa M, Herber M, Buscombe J: Myocardial uptake of Tc-99m HDP in a patient with prostate carcinoma. Nucl Med Rev Cent East Eur; 2009;12(2):78-80
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myocardial uptake of Tc-99m HDP in a patient with prostate carcinoma.
  • In this case report we present an unusual appearance of myocardial uptake of Tc-99m HDP in a 59-year-old renal transplant patient who was imaged while looking for metastases from adenocarcinoma of the prostate.
  • Subsequent investigation demonstrated no obvious cause for this appearance, such as myocardial disease or metastatic cancer.
  • [MeSH-major] Heart / radionuclide imaging. Myocardium / metabolism. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / radionuclide imaging. Technetium Tc 99m Medronate / analogs & derivatives

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20235058.001).
  • [ISSN] 1506-9680
  • [Journal-full-title] Nuclear medicine review. Central & Eastern Europe
  • [ISO-abbreviation] Nucl Med Rev Cent East Eur
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 72945-61-0 / technetium Tc 99m hydroxymethylene diphosphonate; X89XV46R07 / Technetium Tc 99m Medronate
  • [Number-of-references] 16
  •  go-up   go-down


94. Dallinger B, Würnschimmel E: [Appearance of carcinosarcoma after radiotherapy for local recurrence after radical prostatectomy. Case report and review of the literature]. Urologe A; 2010 Jun;49(6):750-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinosarcoma of the prostate is an extremely rare tumor.
  • In the case of rapid tumor progression, especially after radiation therapy to the pelvis or after hormone deprivation therapy because of prostate cancer, this tumor entity should be considered, and immediate histological confirmation is required.
  • We report about the first case of a carcinosarcoma after salvage radiation therapy for local recurrence of adenocarcinoma of the prostate years after radical prostatectomy.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Carcinosarcoma / diagnosis. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Second Primary / diagnosis. Prostatectomy. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / radiotherapy. Prostatic Neoplasms / surgery. Salvage Therapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1985 Jan;133(1):58-60 [3917295.001]
  • [Cites] Hinyokika Kiyo. 2007 Nov;53(11):817-9 [18051809.001]
  • [Cites] Am J Surg Pathol. 2006 Oct;30(10):1316-21 [17001164.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2006;9(2):195-7 [16568146.001]
  • [Cites] Urologe A. 2008 Nov;47(11):1441-6 [18806991.001]
  • [Cites] Am J Surg Pathol. 1993 Apr;17(4):342-9 [8494104.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1035-42 [8625205.001]
  • [Cites] J Urol. 2003 Jan;169(1):157-63 [12478126.001]
  • [Cites] Tech Urol. 2001 Dec;7(4):294-5 [11763492.001]
  • [Cites] Urology. 2009 Sep;74(3):540-1 [19589566.001]
  • [Cites] Ann Diagn Pathol. 2008 Apr;12(2):142-5 [18325477.001]
  • [Cites] Urol Int. 1997;59(1):50-2 [9313326.001]
  • [Cites] J Urol. 2006 Nov;176(5):2025-31; discussion 2031-2 [17070244.001]
  • [Cites] Int J Urol. 2003 Feb;10(2):108-13 [12588610.001]
  • [Cites] Eur Urol. 2006 Dec;50(6):1357-9 [16814927.001]
  • [Cites] Urologe A. 2006 Apr;45(4):474-81 [16465521.001]
  • [Cites] J Urol. 2006 Nov;176(5):2033-8; discussion 2038-9 [17070247.001]
  • [Cites] Ann Urol (Paris). 1999;33(4):263-7 [10510708.001]
  • [Cites] BJU Int. 2008 Nov;102(10):1369-74 [18793296.001]
  • [Cites] Onkologie. 2002 Dec;25(6):558-61 [12566902.001]
  • [Cites] J Urol. 2008 Jan;179(1):91-5; discussion 95 [17997457.001]
  • [Cites] JSLS. 2007 Jan-Mar;11(1):109-12 [17651569.001]
  • (PMID = 20237907.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


95. Lawton CA, Bae K, Pilepich M, Hanks G, Shipley W: Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02. Int J Radiat Oncol Biol Phys; 2008 Feb 1;70(2):437-41
Hazardous Substances Data Bank. GOSERELIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02.
  • PURPOSE: Late gastrointestinal (GI) and genitourinary (GU) morbidity from external beam irradiation used to treat adenocarcinoma of the prostate continue to be a concern of physicians and patients alike.
  • In addition, for locally advanced/high-risk cancer, the appropriate use of hormonal manipulation in addition to radiation therapy (RT) may increase toxicity.
  • CONCLUSIONS: These data show that external beam radiation therapy remains a safe option for locally advanced/high-risk prostate cancer, and the use of hormonal manipulation does appear to be protective for GU and GI toxicity depending upon length of treatment.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52 [11483335.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1843-7 [12085173.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3972-8 [14581419.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):59-67 [14697421.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Sep;21(4):935-9 [1917622.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [7713792.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90 [15817329.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2497-504 [18413638.001]
  • (PMID = 17881145.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] None / None / / U10 CA037422-12; United States / NCI NIH HHS / CA / U10 CA037422-12
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0F65R8P09N / Goserelin; 76W6J0943E / Flutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS37757; NLM/ PMC2917176
  •  go-up   go-down


96. Osunkoya AO, Adsay NV, Cohen C, Epstein JI, Smith SL: MUC2 expression in primary mucinous and nonmucinous adenocarcinoma of the prostate: an analysis of 50 cases on radical prostatectomy. Mod Pathol; 2008 Jul;21(7):789-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC2 expression in primary mucinous and nonmucinous adenocarcinoma of the prostate: an analysis of 50 cases on radical prostatectomy.
  • The expression of mucin (MUC2) in prostate cancer has not been well studied previously and may be of prognostic and pathobiologic significance.
  • It is, however, well known that MUC2 expression in mucinous pancreatic and breast cancer represents an indolent pathway since these tumors have a significantly better outcome than their conventional counterparts.
  • Twenty-five cases each of Gleason pattern 3 and 4 mucinous adenocarcinoma of the prostate defined by greater than 25% mucinous component and nonmucinous adenocarcinoma of the prostate were obtained from the surgical pathology files of the Johns Hopkins Hospital and Emory University Hospital.
  • MUC2 was expressed in all 25 cases (100%) of mucinous adenocarcinoma of the prostate, irrespective of the Gleason pattern.
  • In contrast, MUC2 expression was significantly lower in nonmucinous adenocarcinoma of the prostate, detected in only 6/25 cases as a focal finding, while 19/25 (76%) of nonmucinous adenocarcinoma of the prostate were completely negative for MUC2 (P<0.01).
  • In six cases that showed focal positivity, MUC2 was expressed in areas with Gleason pattern 3 cancer with extensive mucinous fibroplasia (one case) and prominent intraluminal mucin (five cases).
  • Mucinous adenocarcinoma of the prostate shows diffuse expression of MUC2, a known tumor suppressor, which is not present in either normal prostate or the majority of conventional adenocarcinomas of this organ.
  • This indicates that mucinous adenocarcinoma of the prostate is indeed of the 'colloid type' akin to those in other exocrine organs.
  • It is highly conceivable that this de novo expression of MUC2 has a role, not only in the mucinous differentiation of these tumors and their colloid pattern, but also in their relatively indolent behavior that has been recently elucidated.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Biomarkers, Tumor / metabolism. Mucins / metabolism. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Humans. Immunoenzyme Techniques. Male. Middle Aged. Mucin-2. Prostate / anatomy & histology. Prostate / metabolism. Prostatectomy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487999.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


97. Martínez-Rodríguez M, Ramos D, Soriano P, Subramaniam M, Navarro S, Llombart-Bosch A: Poorly differentiated adenocarcinomas of prostate versus high-grade urothelial carcinoma of the bladder: a diagnostic dilemma with immunohistochemical evaluation of 2 cases. Int J Surg Pathol; 2007 Apr;15(2):213-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated adenocarcinomas of prostate versus high-grade urothelial carcinoma of the bladder: a diagnostic dilemma with immunohistochemical evaluation of 2 cases.
  • The differential diagnosis between carcinoma of the urinary bladder and adenocarcinoma of the prostate can be difficult, especially in the poorly differentiated forms infiltrating the neighboring organs.
  • The first is an infiltration of the bladder by a poorly differentiated adenocarcinoma of the prostate, which was clinically suspected as a papillary urothelial neoplasm.
  • The second is a collision tumor composed of prostatic adenocarcinoma and urothelial carcinoma observed on a core needle biopsy of the prostate.
  • In both cases, a large panel of immunohistochemical markers were used and demonstrated positivity for prostate-specific antigen and alpha methyl racemase in the prostatic carcinomas and immunoreactivity for CK7, CK20, Ag 34betaE12, and p53 in the urothelial carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Transitional Cell / pathology. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Male. Neoplasms, Multiple Primary. Prostate-Specific Antigen / metabolism. Racemases and Epimerases / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17478786.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


98. Epstein JI: Precursor lesions to prostatic adenocarcinoma. Virchows Arch; 2009 Jan;454(1):1-16
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor lesions to prostatic adenocarcinoma.
  • High-grade prostatic intraepithelial neoplasia (PIN) is the one well-documented precursor to adenocarcinoma of the prostate.
  • High-grade PIN is also differentiated from invasive acinar (usual) and ductal adenocarcinoma.
  • The incidence of high-grade PIN, its relationship to carcinoma (including molecular findings), and risk of cancer on rebiopsy are covered in detail.
  • Finally, intraductal carcinoma of the prostate, a controversial entity, is discussed and differentiated from high-grade PIN.
  • [MeSH-major] Adenocarcinoma / pathology. Precancerous Conditions / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / pathology. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Intraepithelial Neoplasia / pathology. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):840-8 [9669346.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):882-8 [17527075.001]
  • [Cites] J Clin Pathol. 2006 Apr;59(4):437-9 [16567473.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):929-33; discussion 933 [16469583.001]
  • [Cites] Urology. 1995 Dec;46(6):837-42 [7502426.001]
  • [Cites] Urology. 1997 Apr;49(4):558-63 [9111625.001]
  • [Cites] Eur Urol. 1999;35(5-6):474-8 [10325508.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12):1534-9 [11717544.001]
  • [Cites] J Urol. 2006 Jan;175(1):121-4 [16406886.001]
  • [Cites] BJU Int. 2003 Mar;91(4):350-4 [12603413.001]
  • [Cites] Am J Surg Pathol. 2000 Jan;24(1):140-4 [10632499.001]
  • [Cites] Urology. 2004 Mar;63(3):503-8 [15028446.001]
  • [Cites] Int J Cancer. 1997 Dec 10;73(6):808-11 [9399656.001]
  • [Cites] BJU Int. 2007 Apr;99(4):765-9 [17378840.001]
  • [Cites] Hum Pathol. 1991 Jul;22(7):644-52 [1712748.001]
  • [Cites] Am J Surg Pathol. 1989 May;13(5):389-96 [2469333.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2118-24 [2004331.001]
  • [Cites] Hum Pathol. 2006 Mar;37(3):292-7 [16613324.001]
  • [Cites] Prostate. 2000 Apr 1;43(1):11-9 [10725861.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2008;11(1):20-31 [17909565.001]
  • [Cites] Hum Pathol. 2002 May;33(5):518-23 [12094377.001]
  • [Cites] Am J Surg Pathol. 1985 Aug;9(8):595-609 [4091189.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):629-33 [15105651.001]
  • [Cites] Cancer. 1969 Jan;23(1):24-34 [5763258.001]
  • [Cites] In Vivo. 1994 May-Jun;8(3):439-43 [7803731.001]
  • [Cites] Urology. 2006 Oct;68(4):800-3 [17070356.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):111-9 [2416422.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):645-59 [7686348.001]
  • [Cites] Urology. 2007 Dec;70(6):1100-3 [18158026.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1291-6 [11283929.001]
  • [Cites] Mod Pathol. 1996 Jul;9(7):742-51 [8832557.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):788-94 [2433020.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):389-91 [9458077.001]
  • [Cites] J Urol. 2000 Mar;163(3):819-23 [10687984.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):794-801 [11395558.001]
  • [Cites] Am J Surg Pathol. 1995 Aug;19(8):873-86 [7611534.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1170-81 [15498784.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1184-8 [16931964.001]
  • [Cites] Eur Urol. 2005 Sep;48(3):379-85 [15961218.001]
  • [Cites] Prostate. 2000 Sep 1;44(4):265-70 [10951489.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):298-310 [8454275.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):389-95 [11331955.001]
  • [Cites] Am J Surg Pathol. 1986 Oct;10(10):665-71 [3766845.001]
  • [Cites] Cancer Lett. 1999 Jul 1;141(1-2):173-8 [10454259.001]
  • [Cites] Am J Surg Pathol. 2008 Jul;32(7):1060-7 [18496142.001]
  • [Cites] J Urol. 1997 Jul;158(1):12-22 [9186314.001]
  • [Cites] Hum Pathol. 2005 May;36(5):480-5 [15948114.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):802-14 [8669528.001]
  • [Cites] BJU Int. 2007 Apr;99(4):770-4 [17233800.001]
  • [Cites] BJU Int. 2004 Sep;94(4):528-33 [15329106.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1415-8 [12352407.001]
  • [Cites] Urology. 2005 Apr;65(4):745-9 [15833520.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1215-22 [9331295.001]
  • [Cites] Urology. 1997 Sep;50(3):355-9 [9301697.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):1008-13 [15297968.001]
  • [Cites] Hum Pathol. 1986 Jan;17(1):64-71 [3943853.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):435-40 [9130990.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):899-906 [16607376.001]
  • [Cites] Cancer. 1986 Oct 15;58(8):1714-9 [3756794.001]
  • [Cites] Urology. 2001 Dec;58(6):999-1003 [11744476.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 1):379-85 [8326560.001]
  • [Cites] J Urol. 2008 May;179(5):1751-5; discussion 1755 [18343427.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2617-22 [18451224.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):967-71 [10487854.001]
  • [Cites] Int J Oncol. 2005 Jan;26(1):267-74 [15586249.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1528-35 [16980940.001]
  • [Cites] J Urol. 2001 May;165(5):1409-14 [11342887.001]
  • [Cites] Prostate. 1996 Aug;29(2):117-34 [8700801.001]
  • [Cites] Neoplasia. 2006 Oct;8(10 ):826-32 [17032499.001]
  • [Cites] Am J Surg Pathol. 1992 Dec;16(12):1205-14 [1281386.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1079-85 [11474294.001]
  • [Cites] Int Urol Nephrol. 2007;39(1):189-95 [16835725.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):275-89 [15323145.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3966-71 [8508361.001]
  • [Cites] J Urol. 2005 Oct;174(4 Pt 1):1390-4; discussion 1394; author reply 1394 [16145444.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):820-34 [16469560.001]
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):147-55 [11176063.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):360-79 [14739906.001]
  • [Cites] Can J Urol. 2006 Oct;13(5):3255-60 [17076947.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1119-23 [9781651.001]
  • [Cites] J Urol. 1995 Oct;154(4):1295-9 [7544835.001]
  • (PMID = 19048290.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 85
  •  go-up   go-down


99. Schneider A, Kollias A, Woziwodzki J, Stauch G: [Testicular metastasis of a metachronous small cell neuroendocrinic prostate cancer after anti-hormonal therapy of a prostatic adenocarcinoma. Case report and literature review]. Urologe A; 2006 Jan;45(1):75-80
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular metastasis of a metachronous small cell neuroendocrinic prostate cancer after anti-hormonal therapy of a prostatic adenocarcinoma. Case report and literature review].
  • [Transliterated title] Hodenmetastase eines metachronen kleinzelligen neuroendokrinen Prostatakarzinoms nach Hormontherapie eines Adenokarzinoms der Prostata. Fallbericht und Literaturübersicht.
  • Metastases are sometimes found in cancers of the lung, gastrointestinal tract, kidney, skin and prostate.
  • Less than about 200 cases of testicular metastasis of prostate cancer have been described in the literature.
  • This is this a very small number in comparison to the high incidence of prostate cancer and the vast number of orchiectomies for operative hormone deprivation in advanced cases.
  • The testicle metastases described are mostly unilateral and are often found as ductal carcinoma of the prostate.
  • In our case, the testicular metastasis from a small cell prostate carcinoma appeared 2.5 years after androgen deprivation of an adenocarcinoma of the prostate.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / secondary. Neoplasms, Second Primary / pathology. Prostatic Neoplasms / pathology. Testicular Neoplasms / pathology. Testicular Neoplasms / secondary

  • Genetic Alliance. consumer health - Testicular cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Chir Gynaecol Fenn. 1969;58(2):172-5 [5370000.001]
  • [Cites] Int J Urol. 1997 Jan;4(1):104-5 [9179680.001]
  • [Cites] Cancer. 1972 Aug;30(2):481-5 [5051673.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):238-42 [10757334.001]
  • [Cites] Urologe A. 1985 Sep;24(5):287-90 [4060378.001]
  • [Cites] J Urol. 1989 Oct;142(4):1003-5 [2677407.001]
  • [Cites] Cancer. 1973 Aug;32(2):447-9 [4722923.001]
  • [Cites] Scand J Urol Nephrol. 1983;17(2):249-51 [6612245.001]
  • [Cites] Isr J Med Sci. 1990 Oct;26(10):583-5 [2249937.001]
  • [Cites] Can J Surg. 1986 Sep;29(5):359-61 [3756659.001]
  • [Cites] Br J Urol. 1990 Aug;66(2):205-7 [2390707.001]
  • [Cites] South Med J. 1971 Sep;64(9):1128-30 [5096298.001]
  • [Cites] Urol Int. 1987;42(1):77-8 [3590409.001]
  • [Cites] J Surg Oncol. 1983 Dec;24(4):322-4 [6361390.001]
  • [Cites] Urology. 1988 Oct;32(4):357-60 [3176228.001]
  • [Cites] Urologe A. 1999 May;38(3):279-81 [10407989.001]
  • [Cites] Urol Int. 1987;42(1):79-80 [3590410.001]
  • [Cites] Urology. 1990 Dec;36(6):526-30 [1701066.001]
  • [Cites] Urology. 1983 Jun;21(6):570-2 [6868228.001]
  • [Cites] J Indian Med Assoc. 1988 Apr;86(4):105-7 [3171198.001]
  • [Cites] Urology. 1981 Dec;18(6):607-8 [7314363.001]
  • [Cites] Int Urol Nephrol. 1995;27(5):593-6 [8775044.001]
  • [Cites] Histopathology. 1979 Jan;3(1):31-7 [428920.001]
  • [Cites] J Urol. 1957 Jul;78(1):58-64 [13449990.001]
  • [Cites] Br J Urol. 1995 Jun;75(6):803-4 [7613847.001]
  • [Cites] J Urol. 1969 Oct;102(4):465-8 [5343486.001]
  • [Cites] Urology. 1989 Apr;33(4):322-3 [2929068.001]
  • [Cites] Cancer. 2002 May 15;94(10):2610-7 [12173328.001]
  • (PMID = 16307224.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors
  • [Number-of-references] 32
  •  go-up   go-down


100. Matousková M: [Prostate cancer]. Klin Onkol; 2008;21(5):280-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostate cancer].
  • [Transliterated title] Karcinom prostaty.
  • Malignant prostate tumors rank with its incidence among the most frequent tumors in man in Czech Republic.
  • Adenocarcinoma of the prostate due to its unusual behavior occupy especial position among solid tumors.
  • After the introduction of PSA in the diagnostic methods we can gradually see shift of the new cases of prostate cancer to the localised stage.
  • Movement to less localized stage diminishes the chance of recovery, but even the metastatic adenocarcinoma can be stabilised at least for some time.
  • The aim of therapy of hormonal refractory cancer is to maintain good quality of life and in some prolongation of survival.
  • [MeSH-major] Prostatic Neoplasms

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19202959.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 12
  •  go-up   go-down






Advertisement